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The biological basis of human intelligence is largely a mystery, but likely 
required evolutionary adaptations to achieve the information processing capacity 
needed to expand the complexity of cognition among species. The link between 
evolutionary expansion of signaling complexity in the brain and cognition has 
largely focused on neuronal mechanisms, in part because information processing 
has historically been attributed to these cells. However, astrocytes are emerging 
as a second type of brain cell that is capable of processing information due to 
their capacity to release glutamate and, thereby, regulate neural circuits. Hence, 
a modern question is whether astrocytes contributed to the signaling complexity 
required for sophisticated forms of cognition. The glutamate release mechanism 
system xc- (Sxc) is the ideal mechanism to investigate this question because it is 
evolutionarily novel to vertebrate species and it is expressed by astrocytes. The 
central hypothesis tested herein is that Sxc increased the complexity of 
glutamate signaling and is required for behavior requiring complex cognition. To 
test, a genetically modified rat with Sxc activity eliminated was generated (MSxc 
rats). Phenotyping revealed that loss of Sxc activity produced changes in 
behavior that reflect diminished cognition or top-down processing including 
impaired reversal learning, set-shifting, and attentional allocation. Remarkably, 
loss of Sxc did not impact central regulation of metabolism, Pavlovian 
conditioning, instrumental conditioning, locomotor activity, and novel-object 
recognition.  Additionally, Sxc is integral to the regulation of neural networks. In 
the nucleus accumbens, we found that a loss of Sxc altered synaptic strength in 
a circuit specific manner.  Further, we found that Sxc-mediated glutamate release 
is regulated by presynaptic (the neuropeptide PACAP), postsynaptic 
(endocannabinoid) and hormonal (glucocorticoids) signaling mechanisms. 
Further interrogation of Sxc regulation by PACAP revealed that this neuropeptide 
acts on both neurons and astrocytes to facilitate bidirectional neuron-astrocyte 
signaling between Sxc and extrasynaptic NMDA receptors. The in vivo relevance 
of this mechanism is established by our findings that PACAP microinjected into 
the nucleus accumbens attenuates cocaine-primed reinstatement, and the 
regulation of this behavior requires both Sxc and NMDA receptors.  These 
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The Burden of Cognitive Disorders Represents an Unmet Medical Need  
Neuroscience research has the potential to greatly reduce the burden of 
neurological disorders by discovering new molecular targets to replace the 
current therapeutic strategies that have failed to reduce disease burden. As of 
2016, the World Health Organization (WHO) has established neurological 
disorders, including mental and behavioral disorders, as one of the leading 
causes of disease burden worldwide and in the United States as measured by 
disability-adjusted life years (DALYs) (Geneva, 2018). DALYs are a measure of 
the number of years of life lost to premature mortality and the years of life lost 
due to disability in the given population (Figure 1-1A). Of these neurological 
disorders, mental and behavioral disorders such as substance abuse, anxiety, 
depression, and schizophrenia contribute the greatest disease burden (Figure 1-
1B). The high proportion of DALYs for mental and behavioral disorders is 
suggestive of a major medical need that is unmet by the current therapeutic 
strategies used. Given that the unmet medical need of CNS disorders has not 
decreased despite a more advanced understanding of the brain, a paradigm shift 
in both research focus and therapeutic strategy may be required. 
Arguably, the most efficient strategy to reduce disease burden will involve 
researching and therapeutically targeting the most debilitating and common 





disorders. This ideology is supported by a recent change in research philosophy 
established by the National Institute of Mental Health called Research Domain 
Criteria (RDoC). One of the principle aims of RDoC is to identify the fundamental 
and discrete components underlying multiple disorders that can be readily 
studied by researchers with the goal of more efficiently reducing disease burden 
(Cuthbert & Insel, 2013). This is in contrast to canonical approaches where 
research focus was aimed towards studying the underlying basis of multi-faceted 
diseases such as depression or schizophrenia which are exceptionally difficult to 
model in rodents. Given this, RDoC has the potential to transform neuroscience 
research and therapeutic strategies through revealing the neurobiological basis 
of discrete brain functions (e.g., cognitive control) which could lead to improved 
patient care for multiple diseases that share a particular symptom.    
Figure 1-1: WHO 2016 percent of total disease-adjusted life years (DALYs) lost to major 
diseases in the United States of America. A, Data was tabulated from the 2016 WHO 
estimates for the top 10 diseases with the greatest life burden. B, Data depicts proportion of 
DALYs under the mental/behavioral disorder category. Substance abuse disorders include 
opioid and alcohol use. 




Substance abuse, depression, anxiety, and schizophrenia all share a 
debilitating common symptom, cognitive dysfunction (Millan et al., 2012). 
Cognition represents a complex array of discrete forms of brain function ranging 
from simple forms of learning and memory to much more complex forms that are 
often collectively referred to as executive functions such as self-control and 
selective attention (Diamond, 2013; MacLean, 2016; Ralph, Jefferies, Patterson, 
& Rogers, 2017).  As such, cognition is a type of brain function that is highly 
amendable to an RDoC approach in that researchers can focus on discrete 
cognitive processes (e.g. self-control) that may benefit multiple disorders. Thus, if 
we can understand the cellular and molecular mechanisms underlying discrete 
cognitive processes in the brain, we can develop improved therapies and 
significantly reduce the disease burden of cognitive disorders. Unfortunately, 
uncovering the basis of cognition is complicated by the brain being an 
exceptionally complex biological system which has stymied the emergence of 
successful therapeutics (Millan et al., 2012). 
Establishing the Importance of Glutamate and Astrocytes to Cognition 
 Our incomplete understanding of the human brain and more specifically 
intercellular communication is a fundamental barrier in the development of 
disease modifying therapeutics that are needed to mitigate the impact of 
cognitive disorders (Sundstrom, 2007). Central to this endeavor is thoroughly 
revealing the molecular, cellular, and structural components of intercellular 
communication which collectively dictate how information is transferred from cell 
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to cell within neural circuits; especially since neurotransmitter receptors are the 
most common target for CNS therapeutics (Raiteri, 2006).  
Due to the mathematical complexity created by billions of cells 
communicating across trillions of synapses, the analysis of nervous system 
evolution may provide useful insights into the organizational and signaling 
principles of the vertebrate brain that engendered enhanced cognitive abilities 
which may allow us to refine our therapeutic targets (Bosch et al., 2017; Emes et 
al., 2008; Herculano-Houzel, 2012; Hoshiba, Wada, & Hayashi-Takagi, 2017; 
Tang, Nyengaard, De Groot, & Gundersen, 2001). At the molecular level, 
phylogenetic studies have detected several classical neurotransmitters present in 
vertebrates such as glutamate, gamma-aminobutyric acid (GABA), histamine, 
and monoamines in at least some of the basal metazoan clades which suggests 
each of these molecules were essential components during the evolution of the 
nervous system (Moroz, 2009, 2015; Moroz & Kohn, 2016; J. F. Ryan & Chiodin, 
2015; J. F. Ryan et al., 2013). However, the amino acid neurotransmitters 
glutamate and GABA are unique relative to histamine and monoamines. First, 
these neurotransmitters often directly activate ligand-gated ion channels to 
produce rapid changes in the excitation state of neurons. Second, glutamate and 
GABA are expressed in most if not all neural circuits in the brain. Because of this, 
glutamate and GABA are often modeled as the primary excitatory and inhibitory 
neurotransmitters, respectively, and are involved in most forms of information 
transfer in vertebrate nervous systems (Goetz, Arslan, Wisden, & Wulff, 2007; 
Traynelis et al., 2010). In further support, disrupted glutamate signaling has been 
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linked to cognitive dysfunction seen in schizophrenia, bipolar disorder, 
depression and substance abuse and has therefore driven research focus 
towards therapies that target glutamate receptors and transporters (Dauvermann, 
Lee, & Dawson, 2017; Kalivas, 2009; C.-T. Li, Yang, & Lin, 2019).  Thus, as it 
relates to intercellular communication, information transfer and cognitive 
processing, understanding the forces influencing glutamate signaling will be 
essential to any endeavor seeking to resolve how and why cognitive disorders 
emerge. 
Evolutionary adaptations to nervous systems enabling increased 
computational capacity of cellular networks and improved energy efficiency were 
likely crucial to phylogenetic gains in cognitive ability (Bosch et al., 2017; Emes 
et al., 2008; Niven & Laughlin, 2008; T. J. Ryan & Grant, 2009; Yu & Yu, 2017).  
For example, a key evolutionary event in the expansion of intercellular signaling 
in complex nervous systems was the recruitment of astrocytes to the processing, 
integration, and storage of information in conjunction with providing needed 
metabolic and structural support to neural networks (Alvarellos-Gonzalez, Pazos, 
& Porto-Pazos, 2012; Min, Santello, & Nevian, 2012; Oberheim, Wang, Goldman, 
& Nedergaard, 2006; Porto-Pazos et al., 2011). To achieve this, astrocytes are 
capable of monitoring the activity of thousands to millions of synapses due to the 
expression of most of the traditional neurotransmitter receptors and are capable 
of integrating this information and communicating back to neurons through the 
release of a variety of neuroactive substances (Bormann & Kettenmann, 1988; 
Cahoy et al., 2008; Clarke & Barres, 2013; Glaum, Holzwarth, & Miller, 1990; 
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Grybko, Sharma, & Vijayaraghavan, 2010; Navarrete & Araque, 2010; Oberheim 
et al., 2006; Ogata & Kosaka, 2002; Pruss, Akeson, Racke, & Wilburn, 1991; 
Shen & Yakel, 2012; von Blankenfeld & Kettenmann, 1991; Zanassi, Paolillo, 
Montecucco, Avvedimento, & Schinelli, 1999). Importantly, astrocytes can 
leverage glutamate as a signaling molecule to regulate neural networks while 
also using it as a metabolic substrate to provide energy for high intensity 
information processing. As such, glutamatergic signaling by astrocytes should be 
seriously considered for their potential role in cognition.  
Intriguingly, the phylogenetic increases in the complexity of central 
nervous systems was accompanied by dramatic changes in astrocytes or glial 
cells. For example, C. elegans expresses 0.2 glia for every neuron, whereas the 
brain of H. sapiens has 1.4 glia for every neuron (Nedergaard, Ransom, & 
Goldman, 2003). As a result, glia are the most abundant cell type in the human 
brain (Herculano-Houzel, 2012). Remarkably, the evolution of astrocytes 
occurred on a pace rapid enough that astrocytes can even be distinguished 
between closely related species. For example, human cortical astrocytes are 
reported to be 2.6-fold larger in diameter, extend 10-fold more primary 
processes, and propagate intracellular signals (i.e., Ca2+ waves) four-fold faster 
than rodent astrocytes.  The human brain even has anatomically-defined 
subclasses of astrocytes that are not found in rodents (Oberheim et al., 2009). 
Hence, there is a fundamental need to understand how glutamate signaling 
between neurons and astrocytes regulates the function of complex brains 
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(Alvarellos-Gonzalez et al., 2012; Min & Nevian, 2012; Oberheim et al., 2009; 
Oberheim et al., 2006).   
Over the past few decades, astrocytes have been found to contribute to 
virtually every aspect of brain function, including neural development, synapse 
formation, synapse pruning, synaptic plasticity, glutamate signaling, gating of 
neural circuits for excellent reviews (Allen & Barres, 2005; Christopherson et al., 
2005; Haydon, Blendy, Moss, & Rob Jackson, 2009; Oberheim et al., 2006; 
Papouin, Dunphy, Tolman, Foley, & Haydon, 2017; Perea, Sur, & Araque, 2014; 
Porto-Pazos et al., 2011; Poskanzer & Yuste, 2011). Despite the broad functional 
role of these cells, the potential for these cells to underlie cognition is a new 
concept (Santello, Toni, & Volterra, 2019). The following sections will discuss the 
functional relationships between astrocytes and neurons and how they rely on 
glutamate for information transfer and how glutamate signaling from these cells 
may impact the information processing capacity of neural circuits and 
consequently impact cognition. Figure 1-2 represents some of the key 
components of glutamate signaling within the glutamate synapse. This model is 
meant to set the framework for what is known about glutamatergic signaling and 













A Brief Overview of Glutamate Metabolism in the Tripartite 
Glutamate may have evolved into the primary excitatory neurotransmitter 
in the brain because it is highly abundant and couples key cellular processes 
such as energy and antioxidant production needed for the efficient expansion of 
nervous systems (Moroz & Kohn, 2016).  
 Astrocytes serve as the major source of metabolically derived glutamate 
in the brain and have an efficient network of transporters and enzymes to tightly 
regulate glutamate concentration, metabolism, as well as providing glutamate 
precursors to neurons (Schousboe, Scafidi, Bak, Waagepetersen, & McKenna, 
2014). The canonical glutamate synthesis pathway within the astrocyte involves 
the synthesis of pyruvate from glycolysis which enters the tri-carboxylic acid 
(TCA) cycle to produce α-ketoglutarate (α-KG). Other than continuing through the 
cycle, α-KG can undergo reversible transamination catalyzed by glutamate 
Figure 1-2: Model for glutamate homeostasis within the tri-partite synapse. The cellular 
components of the tri-partite are illustrated by the pre- and post-synaptic terminals and the 
peri-synaptic astrocytic process. Key glutamate enzymes include glutaminase (GA) which 
converts glutamine to glutamate within the pre-synaptic terminal, and glutamine synthetase 
(GS) which converts glutamate to glutamine within astrocytes. Glutamate-cysteine ligase 
(GCL) dimerizes glutamate and cysteine (reduced cystine) and undergoes an additional 
enzymatic step via glutathione synthetase (GTS) to produce glutathione. Glutamate can also 
be converted to α-ketoglutarate and re-enter the TCA cycle to produce ATP. Vesicular release 
mediated by the SNARE complex, excitatory amino acid transporters (EAATs), and the 
cystine-glutamate antiporter system xc- (Sxc) help maintain intra and extracellular glutamate 
balance. Glutamate receptors such as AMPAR, NMDAR, and metabotropic glutamate 
(mGluR) receptors exist within the synaptic and extrasynaptic space and are activated by 
different sources of glutamate. Neurotrophic factors (NTFs) are released by astrocytes and 
signal through their receptors (NTFRs) on neurons to facilitate glutamate receptor expression. 
The foundation for the structural basis of the tripartite synapse is the extracellular matrix 
(ECM). The volume of space between astrocytes and neurons are dictated by tenascins, 
which is critical for the diffusion of glutamate and its ability to access extrasynaptic receptors. 
The synapse is stabilized by neurexins and neuroligins which bridge the pre-synaptic SNARE 
complex and the postsynaptic density (PSD-95) to ensure efficient chemo-electrical transfer of 
information. This is further stabilized by proteins released by astrocytes such as hevin.  
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dehydrogenase to produce glutamate. Glutamate can then be converted into 
glutamine via the astrocyte specific enzyme glutamine synthetase. Glutamine is 
subsequently exported from the cell via system N transport (SN1) where it enters 
the extrasynaptic space awaiting import into presynaptic nerve terminals via 
system A transport (SAT). The accumulated glutamine within the presynaptic 
terminal is converted back into glutamate via glutaminase which can then be 
packaged into vesicles and released into the synaptic cleft. To complete the 
cycle, released glutamate is taken up by sodium dependent astrocytic glutamate 
transporters such as GLT-1. Studies predict that about 85% of the re-
accumulated glutamate within the astrocytic cytosol is converted back into 
glutamine to be released again, with the rest undergoing deamination back into 
α-KG which re-enters the TCA cycle to be recycled for further ATP production 
(Rothman, De Feyter, de Graaf, Mason, & Behar, 2011). This outline of the 
glutamate-glutamine cycle highlights two major roles of glutamate in the 
synergistic relationship between neurons and astrocytes within the peri-synaptic 
space; glutamate is traded as a metabolic molecule in addition to acting as a 
signaling molecule.   
The conversion of glutamate back into α-KG to re-enter the TCA cycle and 
drive ATP production demonstrates its role as a key metabolic currency. The 
ratio of glutamate that is shunted back through the TCA cycle to be oxidized for 
ATP production is dynamically regulated depending on the state of the external 
milieu and internal energy demand of the astrocyte. For example, exogenously 
applied glutamate to astrocyte cultures is converted back into α-KG which in a 
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stepwise manner produces malate then pyruvate which can re-enter the TCA 
cycle as acetyl-CoA (McKenna, 2013). The rate of this phenomenon is 
determined by the extracellular concentration of glutamate. In support, models 
estimate glutamate to have a peak concentration of 1.5 mM following quantal 
release within the synapse with transient extracellular glutamate at about 10 μM 
(Matsui, Jahr, & Rubio, 2005). When glutamate is exogenously applied within this 
range (100 to 500 μM) the astrocyte responds by shuttling a larger proportion of 
glutamate through this oxidative pathway; an increase from about 15.3% at 
baseline to 42.7%. As a result, less glutamate is converted back into glutamine in 
astrocytes which reduces available glutamine for neurons from 85% at baseline 
to 57% (McKenna, Sonnewald, Huang, Stevenson, & Zielke, 1996). The use of 
glutamate as an energy source is theorized to result from the intense energy 
demand within astrocytes. Specifically, the increase in extracellular glutamate 
following phasic neuronal release requires uptake of glutamate via sodium-
dependent astrocyte transporters e.g. GLT-1. This produces a significant sodium 
gradient that requires the utilization of ATP to be corrected via sodium/potassium 
ATPase (McKenna, 2013). 
Models of glutamate release and clearance demonstrate how efficient 
glutamate signaling is in that it has the potential to produce more energy than it 
spends. In support, one quanta of glutamate amounts to about 4000 molecules 
(Riveros, Fiedler, Lagos, Munoz, & Orrego, 1986)  with one quanta being 
released per action potential according to estimates in hippocampal neurons (T. 
A. Ryan & Smith, 1995). This would require 12000 Na+ ions to be extruded 
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following uptake via GLT-1 which amounts to 4000 Na+/K+ ATPase cycles and an 
equivalent number of ATP molecules required to correct the Na+ gradient. Yet, 
the net energy yield for the uptake and oxidation of 1 glutamate molecule is 
about 23-26 ATP; theoretically about 160 glutamate molecules would be 
sufficient to pay for the uptake of 4000 molecules (McKenna, 2013). These 
estimates predict glutamate uptake and oxidation is providing a net excess of 
ATP. Hence, neuron-astrocyte glutamate signaling is highly efficient and 
produces a net excess of energy which can fuel the processing power of neural 
networks required for cognition. 
The abundance of glutamate may also be attributed to its use as a 
substrate for the brain anti-oxidant glutathione (Yelamanchi et al., 2016). 
Importantly, glutamate signaling can pose serious challenges to a nervous 
system due to the metabolic demand it creates and the risk of excitotoxicity 
(Lewerenz & Maher, 2015). In order to counteract this risk, neural cells adapted a 
mechanism to utilize excess glutamate in conjunction with cysteine and glycine to 
produce glutathione. Glutathione is synthesized within astrocytes via a series of 
enzymatic reactions. First, the enzyme glutamate-cysteine ligase (GCL) 
catalyzes the linking of glutamate and cysteine. Next, glutamate-cysteine is 
linked to glycine via the actions of glutathione synthetase (GS) to produce 
glutathione (Bridges, Lutgen, Lobner, & Baker, 2012). Because of the 
involvement of glutamate in the citric acid cycle and biosynthesis of the 
antioxidant glutathione, the selection of glutamate as the primary excitatory 
neurotransmitter may have helped address the balance of excitotoxicity and 
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oxidative stress by efficiently coupling excitatory signaling with energy production 
and oxidative stress defense mechanisms. 
Given these metabolic mechanisms, glutamate was an ideal molecule to 
evolve into the single most abundant amino acid and the primary excitatory 
signal in the vertebrate brain (Abeles, 1991; Braitenberg, Schüz, & Braitenberg, 
1998; Kasthuri et al., 2015; Schousboe, 1981). 
Glutamate Signaling in the Synaptic Cleft 
The glutamate synapse represents the most common functional domain in 
the brain, with estimates placing glutamate at nearly 95% of cortical synapses 
(Kasthuri et al., 2015). The typical glutamate synapse is comprised of a pre-
synaptic terminal, a postsynaptic terminal, and a perisynaptic astrocytic process 
(as depicted Figure 1-2). This section will consider the factors that influence each 
of these components and how they work together in order to efficiently transfer 
information. 
The release of glutamate from the presynaptic neuron occurs in the active 
zone, a specialized region in axonal terminals or boutons containing hundreds of 
proteins that collectively create a highly organized matrix enabling calcium-
dependent release of glutamate (Gronborg et al., 2010; Korber & Kuner, 2016; 
Ribrault, Sekimoto, & Triller, 2011). Ca2+-dependent release involves a series of 
highly orchestrated events that results in the formation of a fusion pore that can 
be shared between the plasma membrane and the membranes of synaptic 
vesicles containing high mM levels of glutamate (Burger et al., 1989; Shupliakov, 
Brodin, Cullheim, Ottersen, & Storm-Mathisen, 1992). The release probability of 
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glutamate is influenced by Ca2+ influx into the presynaptic terminal through 
voltage-gated calcium channels (VGCCs) which are triggered by the arrival of 
action potentials (Branco & Staras, 2009). Ca2+ is received by synaptotagmin, 
which are a class of trans-vesicular membrane associated proteins belonging to 
the SNARE complex that drive vesicular docking, fusion, and release of 
glutamate (Südhof, 2013).  
There are multiple presynaptic glutamate receptors that may enable 
regulation over the pattern and amount of presynaptic glutamate release that 
impact Ca2+ dynamics in the terminal. First, the metabotropic glutamate receptors 
(mGluRs) which belong to the G-protein coupled receptor (GPCR) family can 
impact pre-synaptic glutamate release. There are three major classes of 
mGluRs; group 1,2, and 3 which have varying cellular expression and 
localization. The predominant mGluRs expressed in the pre-synaptic terminal 
belong to group 2 and 3. These groups signal through Gi/Go which inhibit 
adenylate cyclase and consequently ion channels such as VGCCs (Niswender & 
Conn, 2010). For example, application of a group 2 mGluR agonist to 
hippocampal slices reduced pre-synaptic Ca2+ influx which produced a reduction 
in mEPSC frequency at the mossy fiber-CA3 synapse (Kamiya & Ozawa, 1999). 
Ionotropic glutamate receptors may also contribute to pre-synaptic 
regulation of synaptic glutamate release. The two most common ionotropic 
glutamate receptors are n-methyl d-aspartate receptors (NMDARs) and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). NMDARs 
and AMPARs are characterized as tetramers, containing four subunits with a 
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central ion pore. Their principle function is to conduct ionic currents in order to 
rapidly depolarize neurons or trigger intracellular signaling cascades (Traynelis et 
al., 2010).  In the presynaptic compartment, NMDARs are largely involved in 
positively influencing neurotransmitter release. Their effect can either be direct or 
indirect in that activation can directly increase Ca2+ influx into the terminal and 
promote vesicular fusion. Conversely, activation can cause membrane 
depolarization that is sufficient to trigger adjacent VGCCs which indirectly 
increases Ca2+ influx. Regardless of the mechanism, pre-synaptic NMDARs have 
been shown to influence spontaneous and evoked glutamate release (Banerjee, 
Larsen, Philpot, & Paulsen, 2016). Conversely, there is little evidence for pre-
synaptic AMPARs, as their presynaptic expression appears to be brain region 
dependent (Rossi, Maton, & Collin, 2008). 
Estimates suggest that each action potential releases one quanta of 
glutamate that amounts to about 4000 molecules. Other estimations establish a 
range of 3,000-10,000 molecules of glutamate following each action potential 
(Barbour & Hausser, 1997; Clements, 1996; Pendyam, Mohan, Kalivas, & Nair, 
2009). Regardless, this is sufficient to increase extracellular glutamate 
concentration from the nM to the low mM range (0.5-1.0 mM) but only in the 
aspect of the synaptic cleft that is most proximal to the release sites. This results 
in a microdomain of high glutamate concentration that approximates the affinity 
of AMPARs for glutamate (Rusakov, 2001).  
  The distribution of glutamate receptors on the post-synaptic terminal is 
highly organized reflecting, in part, relative affinities for glutamate.  Efficient 
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signaling between the pre and postsynaptic neuron is influenced by the spatial 
distribution of low-affinity AMPAR which are expressed on the closest aspect of 
the post-synaptic membrane relative to the release sites and high-affinity 
NMDAR and mGluRs being expressed more laterally. The localization of 
glutamate receptors is largely driven by a transcellular protein bridge created by 
neurexins, neuroligins and matricellular proteins that link the pre-synaptic release 
machinery (SNARE complex) to the post synaptic density (PSD) that anchors 
AMPARs and NMDARs (Christopherson et al., 2005; Eroglu et al., 2009; Hata, 
Davletov, Petrenko, Jahn, & Südhof, 1993; Kania & Klein, 2016; Kucukdereli et 
al., 2011). The transcellular protein bridge is significant because it ensures the 
intimate localization of glutamate release sites with the post-synaptic terminal, 
which makes synaptic signaling highly efficient. This level of efficiency is 
required, in part because an estimated 50-90% of synaptic glutamate molecules 
exit the cleft within 10-70 ms (Savtchenko & Rusakov, 2004). Thus, the 
concentration of glutamate falls rapidly across temporal and spatial dimensions. 
Activation of low-affinity AMPARs is more sensitive to spatiotemporal regulation 
than high-affinity glutamate receptors such that lateral trafficking of AMPARs 
represents a key form of synaptic plasticity influencing sensitization (for review 
see, Rusakov, Savtchenko, Zheng, & Henley, 2011).  Indeed, when AMPARs are 
experimentally immobilized, they rapidly desensitize in response to glutamate 
application which greatly reduces post-synaptic currents (Heine et al., 2008). As 
a result, AMPARs are ideal targets for signaling mechanisms to exert powerful 
control over the strength of synaptic transmission. 
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 While synaptic AMPARs function to rapidly transmit glutamate signals, the 
function of synaptic NMDARs and mGluRs tend to be slower and are meant to 
augment the function of AMPARs. Importantly, NMDARs are under a unique form 
of regulation relative to AMPARs. Instead of regulation linked to glutamate affinity 
and diffusion, a major regulatory mechanism for NMDARs is the voltage-
dependent physical occlusion of their ion pore by a Mg2+ ion. In order for this 
block to be lifted, sufficient membrane depolarization via AMPARs is required 
(Traynelis et al., 2010). Once lifted, NMDARs can conduct Ca2+ ions which can 
activate a variety of intracellular signaling cascades that activate kinases and 
trigger the synthesis of new proteins. Synaptic mGluRs synergize these effects 
by also contributing to the propagation of Ca2+-dependent effects. Broadly, the 
impact of synaptic NMDARs and mGluRs tend to stabilize the synaptic structure 
and boost AMPAR-mediated signaling in a phenomenon referred to as long-term 
potentiation LTP (Bliss & Collingridge, 1993). Thus, post-synaptic AMPARs, 
NMDARs, and mGluRs synergize to effectively encode pre-synaptic glutamate 
signals. 
While diffusion of glutamate from the synapse represents an important 
phenomenon for the regulation of synaptic signaling, the last component of the 
synapse, the astrocytic process, is involved in synaptic glutamate clearance. It 
has been theorized that for every molecule of glutamate released, roughly 4000 
molecules per quanta, there is an equal number of transporters ready to remove 
glutamate from the cleft. Specifically, the excitatory amino acid transporter 
(EAAT) GLT-1, the most abundant astrocytic glutamate transporter in the brain, 
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assumes the role as the primary glutamate clearance mechanism (Lehre & 
Danbolt, 1998). Intriguingly, recent findings have demonstrated that GLT-1 is a 
highly mobile protein in astrocyte membranes which is functionally relevant to 
controlling glutamate within the synapse. Under periods of low neuronal activity, 
GLT-1 is anchored at the synapse waiting for glutamate to be released. As 
glutamate concentrations climb, GLT-1 binds glutamate and rapidly diffuses out 
of the synapse allowing for unbound transporters to rotate in. Interestingly, when 
GLT-1 is experimentally immobilized, its ability to clear glutamate is not impaired 
but post-synaptic currents are increased, suggesting that GLT-1 has a dual 
function in not only transporting glutamate into the astrocyte, but also moving it 
away from low affinity AMPARs and into the extrasynaptic compartment (Murphy-
Royal et al., 2015). Thus GLT-1 is important for maintaining the sensitivity of 
AMPARs within the synapse and controlling the diffusion of glutamate out of the 
synapse. Thus, the function of the peri-synaptic astrocytic process demonstrates 
how important astrocytes are in the regulation of synaptic glutamate signaling. 
The basic elements of glutamate’s actions in the synaptic cleft involving 
the activity-dependent release, diffusion across a synaptic cleft, and activation of 
postsynaptic receptors resembles what has been in place throughout much of the 
evolution of metazoan nervous systems. In other words, synaptic glutamate is 
among the most ancient of signaling processes (Moroz, 2009, 2015; Moroz & 
Kohn, 2016; J. F. Ryan & Chiodin, 2015; J. F. Ryan et al., 2013). However, 
nervous systems have expanded upon this essential unit of the nervous system 
by increasing the complexity of intercellular communication through establishing 
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a network of glutamate receptors, transporters, and release mechanisms 
distributed outside of the synapse on both neurons and astrocytes.  
Glutamate Signaling in the Extrasynaptic Space 
The opportunity to increase the complexity of signaling in the brain likely 
required extrasynaptic signaling. Estimates suggest that the synaptic cleft 
represents 2% or less of the total interstitial space (Rusakov, Harrison, & 
Stewart, 1998). Evolution has equipped the remaining 98% of interstitial space 
with glutamate receptors, transporters, and release mechanisms that are 
expressed throughout the full extent of neuronal and astrocytic cellular 
membranes, which provides the molecular basis for the diverse forms of 
signaling.  Importantly, the extrasynaptic compartment conveys unique forms of 
information transfer relative to the synapse. As a result, synaptic and 
extrasynaptic glutamate signaling occurring between neurons or between 
neurons and astrocytes can be segregated into functionally distinct, specialized 
signaling zones or microdomains (Dityatev, Seidenbecher, & Schachner, 2010; 
Le Meur, Galante, Angulo, & Audinat, 2007; Malarkey & Parpura, 2008; 
Moussawi, Riegel, Nair, & Kalivas, 2011; Papouin & Oliet, 2014; Wu, Grebenyuk, 
McHugh, Rusakov, & Semyanov, 2012). Given the massive surface area of the 
extrasynaptic compartment, it is physically created by the two most abundant 
cells in the brain: astrocytes and neurons. Of particular interest to this work is the 
contribution of astrocytes to the extrasynaptic space which includes monitoring 
neuronal activity, integrating neuronal information, and transforming that 
information into a functional output to influence the activity of entire neural 
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networks. Astrocytes achieve this through the reception and release of a variety 
of neuroactive substances such as glutamate and trophic factors (e.g., BDNF, 
TGF-β) (Verkhratsky, Matteoli, Parpura, Mothet, & Zorec, 2016).  
Regarding how astrocytes can monitor and integrate neuronal information, 
glutamate that enters the extrasynaptic compartment can gain access to 
receptors present on astrocytes which are largely thought to be mGluRs. 
Notably, the expression of functional ionotropic receptors in astrocytes (primarily 
NMDARs and AMPARs) varies greatly depending on brain region and 
experimental conditions and will not be discussed here (Hoft, Griemsmann, 
Seifert, & Steinhauser, 2014). The two most predominant mGluRs expressed by 
astrocytes are mGluR5 and mGluR3 (Bradley & Challiss, 2012; Schools & 
Kimelberg, 1999) which belong to group 1 and group 2 respectively. MGluR5 
activation by glutamate triggers phospholipase C activity which produces inositol 
triphosphate (IP3) and diacylglycerol (DAG) resulting in Ca2+ release from the 
endoplasmic reticulum. Intriguingly, the Ca2+ response oscillates with mGluR5 
activation, which is dependent on a PKC mediated negative feedback loop which 
momentarily phosphorylates mGluR5 and decouples it from Gαq. Importantly, 
increasing glutamate concentrations has no effect on the frequency or amplitude 
of Ca2+ oscillations once the signaling loop has been initiated. In a sense, this 
cascade is “all or none” and simply encodes the presence of sufficient activity 
from adjacent neurons. The functional consequence of mGluR5 activation and 
these Ca2+ oscillations is still under investigation, but one of the current theories 
suggests that activation of mGluR5 enhances glutamate uptake into the astrocyte 
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via increasing GLT-1 expression which facilitates clearance of extracellular 
glutamate (Devaraju, Sun, Myers, Lauderdale, & Fiacco, 2013; Umpierre, West, 
White, & Wilcox, 2019; Vermeiren et al., 2005). 
MGluR3, while having a different G-protein coupling mechanism, has 
some similarities in function with mGluR5 in astrocytes. Activation of mGluR3 has 
been shown to produce enhancements in glutamate transporter expression 
(Aronica et al., 2003), which suggests that the astrocytic mGluRs serve 
redundant functions in receiving qualitative information about nearby neuronal 
activity and consequently working to reduce the concentration of extracellular 
glutamate. Thus, activation of either receptor can serve as a neuroprotective 
mechanism against glutamate induced excitotoxicity. For example, mGluR3 has 
been shown to increase the production and release of trophic factors such as 
TGF-β and NGF which can act synergistically on adjacent neurons to promote 
survival (Bruno et al., 1998; Ciccarelli et al., 1999). Additionally, mGluR5 
facilitates neuroprotective effects via astrocytes in a model of ischemic stroke 
(Cavallo et al., 2020) With both the actions of both mGluR3 and 5 in astrocytes 
considered, the net effect of glutamate acting on these receptors appears to be 
maintaining extracellular glutamate levels within a safe range while at the same 
time providing neuroprotective factors.  
An emerging principle of brain function is that astrocytes can actively 
release glutamate to regulate neurons (Baker, Xi, Shen, Swanson, & Kalivas, 
2002; Jourdain et al., 2007; Martin, Bajo-Graneras, Moratalla, Perea, & Araque, 
2015). Notably, the actions of glutamate released by astrocytes can be 
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functionally distinct from neuronally derived glutamate due to spatial and 
temporal receptor activation parameters.  In other words, astrocytes may target 
glutamate release to a population of neuronal receptors that are distal from 
synaptic release sites.  These receptors are often embedded in large protein 
complexes and have different functions relative to their synaptic counterparts.  
For example, extrasynaptic NMDARs have been detected in highly-specialized 
protein complexes that are often anchored near adjacent astrocyte processes 
(Petralia et al., 2010; Sah, Hestrin, & Nicoll, 1989), and extrasynaptic NMDARs 
can have effects on the neuron that are opposite to synaptic NMDAR activation 
such as producing an attenuation rather than  enhancement of excitatory output 
(Papouin & Oliet, 2014). Thus, understanding the factors regulating astrocytic 
release of glutamate will be essential to understanding how astrocytes can 
impact neural circuits and consequently behavior.  
The mechanisms of glutamate release from astrocytes fall into two major 
groups: channel/transporter mediated and vesicular mediated (Malarkey & 
Parpura, 2008). For example, the cystine-glutamate antiporter system xc- (Sxc) 
which represents a non-vesicular release mechanism, has been shown to 
release glutamate that can activate pre and post-synaptic glutamate receptors in 
the striatum and hippocampus to regulate synaptic strength (Baker et al., 2002; 
Lewerenz et al., 2013; Williams & Featherstone, 2014). Similarly, ultrastructural 
electron microscopy studies provide evidence for vesicles containing glutamate 
in hippocampal astrocytes proximal to pre-synaptic neuronal NMDARs which 
when activated enhance synaptic glutamate release and strength (Bezzi et al., 
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2004; Jourdain et al., 2007; Xu et al., 2007). Furthermore, TREK-1 and Best1, 
which are both glutamate-permeable channels, serve as fast/phasic and 
slow/tonic mechanisms of glutamate release from astrocytes (Woo et al., 2012). 
The significance of their differing transport velocities is revealed by their 
respective activation of neuronal mGluRs and NMDARs which consequently tune 
synaptic transmission. Given the variety of release mechanisms, a question that 
needs to be resolved is under what specific circumstances do each of these 
mechanisms become active and how might they be linked to or disrupted in 
disease? 
A common underlying factor that enhances glutamate release from 
astrocytes is elevations in astrocytic intracellular Ca2+, which might explain how 
some glutamate release mechanisms in astrocytes become active. As is the case 
in neurons, Ca2+ is the key signal that mediates the fusion of vesicles with the 
membrane via the SNARE complex, so it is likely that astrocytes have a similar 
mechanism so long as the machinery is present. Indeed, electron microscopy 
studies have shown the vesicular glutamate transporter VGLUT1/2 and SNARE 
protein cellubrevin in hippocampal astrocytes (Bezzi et al., 2004). However, the 
relevance of these findings to in vivo function remains a controversial topic. In 
particular, the use of genetically modified mice designed to lack vesicular release 
machinery in astrocytes in experiments seeking to investigate its role in 
regulating neural networks in vivo revealed transgene expression in neurons 
which quelled of the relevance of the findings (Bohmbach, Schwarz, Schoch, & 
Henneberger, 2018; Fujita et al., 2014).  However, even without vesicular release 
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machinery, Ca2+ can also impact transporter-mediated glutamate release such as 
through Best1 (Sun, Tsunenari, Yau, & Nathans, 2002). Likewise, volume-
regulated anion channels (VRACs) are opened during astrocytic swelling which 
can release excitatory amino acids such as glutamate (Kimelberg, Goderie, 
Higman, Pang, & Waniewski, 1990). VRACs do appear to be somewhat sensitive 
to Ca2+, as Ca2+-dependent astrocyte swelling stimulated their opening. While it 
is unknown whether other transport mechanisms have a documented Ca2+ 
sensitivity, it is certainly possible that Ca2+ dependent kinases may regulate 
transporter activity through phosphorylation. More work is needed to explore this 
possibility. 
Glutamate release from astrocytes can occur even in the absence of Ca2+ 
signaling. For example, the purinergic receptor P2X7 is a ligand-gated ion 
channel activated by ATP that is capable of releasing glutamate and is not 
negatively impacted by a lack of Ca2+ (Duan et al., 2003). Additionally, the 
connexin 43 hemichannels, which are capable of transporting glutamate, 
glutathione, ATP, as well as cations do not appear to be activated by Ca2+, rather 
they serve an important role in balancing Ca2+, among other molecules, across 
the cell membrane (Liang et al., 2020).  
Considering the mechanisms of glutamate release from astrocytes and the 
power that they have in regulating neurons, lingering questions arise regarding 
how these components impact cognitive processing and behavior. An emerging 
viewpoint of the field, and the one that will be established by the experiments in 
the following chapters is that neurons and astrocytes work together to dictate 
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how glutamate engages its receptors to regulate neural networks and cognition.  
The overarching question that will be answered by these experiments is whether 
astrocytes were involved in the expansion of cognitive abilities in vertebrates due 
to their ability to process and disseminate information through glutamate. 
Ultimately, do these cells contain the glutamatergic components that enhanced 


























Cognitive deficits contribute to the disease burden associated with 
numerous disorders including mental health, cancer, diabetes, heart disease, 
and obesity (Cannon et al., 2017; Harrison & Wefel, 2018; He, Ryder, Li, Liu, & 
Zhu, 2018; Jones, Gray, & Hemsley, 1992; Lange, Seer, & Kopp, 2017; P. M. 
Moran, Owen, Crookes, Al-Uzri, & Reveley, 2008; Rock, Roiser, Riedel, & 
Blackwell, 2014; Y. Yang, Shields, Guo, & Liu, 2018). Mental health disorders in 
particular such as depression and substance abuse register as leading causes of 
disease burden in high-income countries (DiLuca & Olesen, 2014; Gustavsson et 
al., 2011; Lassek, Weingarten, & Volknandt, 2015; Olesen & Leonardi, 2003; 
WHO, 2008). Considering this, resolving cognitive dysfunction would greatly 
reduce disease burden. While this renders the development of safe, effective 
cognitive pharmacotherapies as a high priority, there has been insufficient 
progress due to critical gaps in our understanding of the cellular and molecular 
basis of cognition in the brain. An emerging viewpoint is that the molecular basis 
of cognition in vertebrates likely arose from the evolutionary enhancement of 
signaling complexity in the brain (Emes et al., 2008; Nithianantharajah et al., 
2013), which may support novel strategies to understand and treat cognitive 
dysfunction.  
The evolutionary expansion of glutamate neurotransmission contributed to 
the signaling complexity needed for the progression of cognitive ability. For 
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example, synaptic glutamate became an important form of intercellular signaling 
early in the evolution of nervous systems and has become the most ubiquitous 
neurotransmitter, as evidenced by its inclusion in nearly 95% of cortical synapses 
(Kasthuri et al., 2015; Moroz et al., 2014; T. J. Ryan & Grant, 2009; Schousboe, 
1981). Indeed, relatively recent adaptations such as the expression of novel, 
functionally distinct NMDAR subunits contributed to enhanced signaling 
complexity in synapses which expanded the amount of information that could be 
encoded by glutamate (Teng et al., 2010). Beyond this, the human brain has 
been further equipped with glutamate receptors and release mechanisms 
(Lewerenz et al., 2013; Malarkey & Parpura, 2008), expressed by non-neuronal 
cells and in non-synaptic domains (Chiu, DeSalle, Lam, Meisel, & Coruzzi, 1999; 
Papouin et al., 2017; Tikhonov & Magazanik, 2009). A major question is whether 
or not these non-synaptic, non-neuronal adaptations are relevant to the 
expansion of signaling complexity within neural networks and were essential to 
the enhanced cognitive ability of higher vertebrates.  
 The acquisition of novel genes encoding astrocytic glutamate-release 
mechanisms that signal within non-synaptic domains may have been key in 
expanding the processing power of neural circuits and consequently, cognitive 
abilities. In support, a human cortical astrocyte contacts millions of synaptic units, 
which is considerably more than neurons and allows them to communicate with 
and regulate entire neural networks (DeFelipe, Alonso-Nanclares, & Arellano, 
2002; Oberheim et al., 2009; Oberheim et al., 2006). Indeed, computational 
models reveal that astrocyte-neuron signaling significantly improves the 
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performance of neural networks, especially when the size of the network or the 
complexity of the information is maximized (Alvarellos-Gonzalez et al., 2012; 
Porto-Pazos et al., 2011).  Additionally, biological studies demonstrate that 
astrocytes exert complex regulation over neural networks, which can include the 
gating of specific circuits or increased network synchronization (H. S. Lee et al., 
2014; Martin et al., 2015; Poskanzer & Yuste, 2016; Sardinha et al., 2017). While 
there are a variety of mechanisms that release glutamate from astrocytes 
(Malarkey & Parpura, 2008) there is a critical gap in our understanding of their 
individual and collective roles in neural network regulation and cognition. 
Consequently, there has only been a recent appreciation for the possibility that 
astrocytes are active players in cognition which is striking considering the degree 
of influence they exert over neural networks (Santello et al., 2019). 
In the studies described in this chapter, we investigated the role of the 
cystine-glutamate antiporter system xc- (Sxc) in the regulation of neural circuits 
and cognition. Sxc releases intracellular glutamate in exchange for extracellular 
cystine (Baker et al., 2002; Warr, Takahashi, & Attwell, 1999). It is a heterodimer 
of the subunits xCT and 4F2hc, which are encoded by the genes Slc7a11 and 
Slc3A2, respectively. Importantly, the xCT subunit serves as the catalytic subunit 
whereas the 4F2hc guides and anchors it in the membrane (de la Ballina et al., 
2016; Sato, Tamba, Ishii, & Bannai, 1999; Shih & Murphy, 2001). Intriguingly, the 
observed expression patterns of Slc7a11 establish Sxc as an evolutionarily-new 
glutamate-release mechanism expressed by astrocytes (Lewerenz et al., 2013; 
Ottestad-Hansen et al., 2018) and is present in brain regions involved in 
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cognitive processing such as the hippocampus, amygdala, prefrontal cortex, and 
nucleus accumbens (Baker, McFarland, Lake, Shen, Tang, et al., 2003; Lutgen 
et al., 2014).  
In the nucleus accumbens core (NAcc), Sxc activity is negatively impacted 
by self-administration of drugs of abuse which has made it a focus for therapeutic 
intervention in substance abuse patients (Kalivas, 2009). In support, Sxc activity 
is reduced following self-administration of cocaine in rats resulting in reduced 
extracellular glutamate in the NAcc. This reduction is thought to produce drug 
seeking through a mGluR2 dependent mechanism whereby a reduction in its 
activity produces a disinhibition of glutamate release from cortical afferents; 
enhancing excitatory drive on NAcc efferents and consequently promoting drug 
seeking (Baker et al., 2002). Intriguingly, restoring extracellular glutamate levels 
using drugs that may target Sxc such as n-acetylcysteine reduces drug seeking 
during drug primed reinstatement tests (Baker, McFarland, Lake, Shen, Tang, et 
al., 2003). The use of n-acetylcysteine has also shown efficacy in clinical models 
of cocaine addiction, where a four-day treatment regimen attenuated cocaine 
craving following an I.V. infusion (Amen et al., 2011).  Furthermore, n-
acetylcysteine has a similar efficacy in preclinical and clinical studies of heroin 
(Zhou & Kalivas, 2008) and nicotine (Schmaal et al., 2011) addiction as well as 
other compulsive disorders such as binge eating (Hurley et al., 2016) and 
Prader-Willi syndrome (J. L. Miller & Angulo, 2014). These studies lend support 
to Sxc having a significant impact on neuronal signaling and behavioral control 
and is a promising therapeutic target. 
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Given the novelty of Sxc expression in animal species, its ability to 
regulate synaptic glutamate, and its potential to influence cognition, we sought to 
further elucidate the biological significance of its expression in a mammalian 
system. To do this, we developed a novel rat strain that lacks functional Sxc 
(Figure 2-1B, MSxc rat).  With this tool, we tested the hypothesis that global 
removal of Sxc in a rat would sufficiently disrupt neural networks and cognition in 
a manner that produces maladaptive behavioral phenotypes. Furthermore, the 
MSxc rat will help resolve whether astrocyte to neuron signaling was a key event 
in achieving the signaling complexity needed for executive function and cognition 
in mammals.  
MATERIALS AND METHODS 
Chemicals: Unless noted, common chemicals and reagents were obtained from 
Sigma Aldrich. 
Animal care and usage: Male Sprague Dawley rats were used for these 
experiments. Housing conditions and experimental protocols were approved by 
Institutional Animal Care and Use Committees at the Medical College of 
Wisconsin or Marquette University, and were carried out according to the US 
National Institutes of Health guidelines. 
SLAC Analysis: mRNA protein coding sequences from the SLC7A11 gene from 
115 organisms were retrieved from Genbank (Benson, Karsch-Mizrachi, Lipman, 
Ostell, & Sayers, 2009). Partial and isoform sequences were left out of this study. 
Sequences were aligned by codon using MUSCLE (Edgar, 2004) in the MEGA6 
software package(Tamura, Stecher, Peterson, Filipski, & Kumar, 2013) and 
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manually reviewed for accuracy. The aligned sequences were run through 
MEGA6 model selection software using a neighbor-joining tree and a maximum-
likelihood statistical method. Gaps were treated by partial deletion and were not 
used for computing tree branch lengths. The K2+G (gamma distributed) model 
was utilized to construct a phylogenetic tree. Pairwise distances were estimated 
with uniform rates and partial deletion of gaps. Bootstrap values were generated 
from 100 replications. A cutoff tree was computed with a minimum bootstrap 
value of 70. Sequence motifs for specific consensus phosphorylation sites were 
searched within the alignment and conservational data was manually extracted 
based on the existence or absence of the site. Determination of sites under 
positive or negative selection was carried out using the Datamonkey web server 
(Delport, Poon, Frost, & Kosakovsky Pond, 2010). SLAC, branch-based SLAC, 
FEL, and an integrative selection analysis (Kosakovsky Pond & Frost, 2005) 
were carried out using a neighbor joining tree at a 0.05 significance level.  
Creation of GFAP:Lck-eGFP transgenic rats: The Sleeping Beauty (SB) 
transposon transgenesis method (Geurts et al., 2010) was used to produce 
transgenic rats on the Sprague Dawley (Crl:SD) background. Briefly, a GFAP 
promoter-driven fusion between the plasma membrane targeting myristolation 
domain of the mouse LCK protein fused to eGFP(Benediktsson, Schachtele, 
Green, & Dailey, 2005) was synthesized (GeneArt) and cloned into a SB 





SB100X transposase mRNA into the pronucleus of fertilized Crl:SD embryos. A 
breeding colony was established harboring a single copy of the transgene 
inserted on rat chromosome 13 enabling robust eGFP expression. To confirm 
expression in situ, a rat was deeply anesthetized and transcardially perfused with 
4% paraformaldehyde. The brain was extracted and sliced at 100 µm and GFP 
signal was visualized using standard fluorescence microscopy.  
Creation of MSxc rats: Zinc-finger nucleases (ZFNs) were designed targeting 
the second exon sequence (TGCTAGCTTTTGTTCgagtcTGGGTGGAACTGC 
TG) to produce small deletions of a limited number of base pairs in the Slc7a11 
gene, where capital letters represent binding sites for the individual ZFN 
monomers, on opposite strands (Figure 2-1). ZFNs were injected into the 
pronucleus of Sprague Dawley (Crl:SD) rat embryos by pronuclear microinjection 
of in vitro-transcribed encoding messenger RNAs and the resulting offspring 
were screened for mutations using a Cel-1 assay and validated by Sanger 
Figure 2-1: Quaternary and primary structure of Sxc and xCT. A, The quaternary 
structure of Sxc is comprised of the heavy chain subunit (4F2hc a.k.a. CD98) and the 
transporter subunit xCT which contains 12 transmembrane domains.  B,  The primary 
structure of the protein coding sequence of xCT. Area highlighted in red defines the target for 
the mutation that created the xCT mutant (MSxc) rat which corresponds to the third 
transmembrane domain seen in A.  
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sequencing as previously described(Geurts et al., 2010) and resulting in single-
step, whole-animal disruption of Slc7a11 (MSxc rats). Deletion of 39 consecutive 
base pairs (GAGGTCTTTGGTCCCTTGCTAGCTTTTGTTCGAGTCTGG) of 
exon 2 was confirmed by Sanger sequencing.  
Tissue Dissociation for FACS: NAc tissue was dissected from male GFAP-lck-
eGFP or WT Sprague Dawley rats and placed into ice-cold Hanks´ Balanced Salt 
Solution without Ca2+ or Mg2+. Tissue was mechanically and enzymatically 
dissociated to obtain single-cell suspension using Neural Tissue Dissociation Kit 
- P (Miltenyi Biotec). 1% BSA, 1mM EDTA and 12.5 U/ml DNase I were added to 
reduce cell clustering. Cells were incubated with 3 µM Calcein Violet 450 AM 
Viability Dye (eBioscience) on ice for 10 minutes to stain live cells. An aliquot 
from each cell suspension was used to determine relative gene expression in 
sorted and unsorted (total) cells. 
Flow Cytometry: FACS analyses were performed using FACSDiva software 
6.1.3 (BD Biosciences). Control samples (tissue obtained from rats lacking the 
GFAP:Lck-eGFP transgene) were analyzed first to identify the range of 
endogenous or background fluorescence intensity. In addition, the gating 
parameters of the flow cytometer were set to isolate live, eGFP+ cells from 
cellular debris, and cell doublets. Note, the eGFP- samples contain all tissue 
excluded from the eGFP+ sample and would be expected to include eGFP- cells, 
cell doublets, fragmented cells, and potentially eGFP+ cells that were not 




RNA Extraction and Amplification of FACS samples: Total RNA from sorted 
cells was isolated using PicoPure RNA Isolation Kit (Thermo Fisher Scientific). 
On column DNase treatment was applied to all samples with the RNase-Free 
DNase Set (Qiagen). RNA quantity and quality were assessed on an Agilent 
2100 Bioanalyzer using Agilent RNA 6000 Pico Chips. Only samples with RNA 
quality of RIN > 7.0 were used. Resulting RNA was amplified and reverse 
transcribed using the cDNA synthesis from cell lysates kit (Lucigen). 
RT-PCR/qPCR: Total RNA was extracted from NAcc tissue samples using Trizol 
reagent and was subsequently treated with DNAse (Life Technologies) to remove 
genomic DNA contamination. RNA purity and quantity were assessed using a 
Nano Vue Plus spectrophotometer (GE Life Sciences). RNA (1 g) from each 
sample was reverse transcribed for PCR (Promega). PCR was conducted using 
GoTaq DNA polymerase (Promega). For analysis of FACS samples, qPCR was 
conducted using SYBR green chemistry (Quantabio) in a 48-well StepOne real-
time PCR system (Applied Biosystems). Primer sequences were as follows: 
Slc7a11 (xCT) forward- 5’ AGG GCA TAC TCC AGA ACA CG 3’; Slc7a11 
reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’; GAPDH forward- 5’ CTC CCA 
TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG TAG GCC ATG AGG TCC 
AC 3’. GFAP forward - 5’ GCA GGT GAG GAA GAA ATG GA 3’; GFAP reverse - 
5’ TAC GAT GTC CTG GGA AAA GG 3’; NeuN forward - 5’ ATC ATA CCA TCG 
GCC CCA CA 3’; NeuN reverse - 5’ GTG AAG CGG CTG TAC CCT CC 3’. 
Western Blotting: NAcc tissue samples obtained from adult WT and MSxc rats 
(i.e., > 90 days old) underwent mechanical homogenization in a sucrose-based 
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buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.4) containing protease and 
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentration for each 
whole cell lysate sample was determined via the bicinchoninic acid assay (BCA). 
Protein (10 g) was resolved in a 7.5% polyacrylamide gel and wet transferred to 
Immobilon PVDF membranes (EMD Millipore). Membranes were immersed for 
one hour in blocking buffer (LiCor) prior to overnight application at +4°C with a 
primary antibody: rabbit anti-mGluR2/3 (Upstate, 1:3000) rabbit anti-EAAT2 
(1:3000) rabbit anti-pT840 GluA1 (Abcam, 1:3,333) rabbit anti-pS845 (Abcam, 
1:1000) mouse anti-GluA1 (EMD Millipore, 1:1000) chicken anti-GAPDH (EMD 
Millipore, 1:10,000) rabbit anti-xCT (generated by Dr. Rothstein, 1:500). 
Secondary antibodies (LiCOR) goat anti-rabbit IR 680 DYE (1:15000) donkey 
anti-mouse IR 800 DYE (1:20,000) and donkey anti-chicken IR 800 DYE 
(1:20,000) were applied for 1 hour at room temperature prior to imaging 
(Odyssey Fc Imaging System, Licor). Band intensity was quantified using LiCOR 
Image Studio software and the resulting data are presented as the target protein 
band intensity divided by the reference protein band intensity. 
Cell Culture: Astrocyte cultures were generated from postnatal day-3 rat pups. 
The striatum was dissected and dissociated using 0.25% trypsin EDTA (Gibco) 
and cultured in 75 cm2 flasks in a humidified incubator at 37°C under 95% O2 5% 
CO2 in Eagles minimum essential medium (Gibco) supplemented with 5% fetal 
bovine serum/5% horse serum (Atlanta Biologicals), Glutamax (Gibco), and 
antibiotics/antimycotics (Gibco). To remove debris and non-astrocytic glia, flasks 
were agitated, and the resulting mono-cell layer was resuspended with 0.25% 
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trypsin EDTA. Cells were counted by hand via a cytometer and seeded in 24-well 
plates coated with poly-D-lysine and laminin at a density of 200,000 cells per 
well.  
14C-L-Cystine and 3H-D-Aspartate uptake assays: These assays were used to 
determine Sxc and EAAT function, respectively. NAcc tissue punches or 
astrocyte cultures obtained from adult WT and MSxc rat were incubated for 20 
minutes in artificial cerebral spinal fluid (aCSF) and maintained at 37oC under 
95% O2 5% CO2 conditions. For D-aspartate uptake, NAcc tissue or cultured 
cells were then incubated for 30 minutes in 1 M 3H-D-aspartate dissolved in 
aCSF. Likewise, for 14C-L-Cystine (1 M), tissue was incubated for 30 minutes. 
For each study, tissue punches or cells were then dissolved in 300 l of 1% 
sodium dodecyl sulfate (SDS). A 200 l aliquot was used for scintillation counting 
(Beckman 6500) and a 25 l aliquot was used for protein determination using the 
BCA assay.  
Cystine-evoked glutamate release assay: In order to measure Sxc function, 
striatal astrocytes (DIV14) were incubated for 30 minutes at 37oC in Na+-free 
buffer containing the following: 116 mM choline chloride, 13.4 mM MgSO4, 1.68 
mM KH2PO4, 2.34 mM CaCl2, 5.49 mM dextrose, 11.9 mM HEPES, 0.2% choline 
bicarbonate, titrated to pH: 7.4 with CeOH. This buffer was used to prevent Na+-
dependent uptake of glutamate. Increasing concentrations of L-cystine 0, 12.5, 
25, 50, 100, 200 M were applied to drive cystine-glutamate exchange by Sxc. 
Media samples (100 l) were collected for subsequent glutamate analysis using 
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high performance liquid chromatography (HPLC). Cells were then dissolved in 
0.5% SDS and total protein for each well was quantified using the BCA method. 
Glutamate HPLC: The concentration of glutamate was quantified by comparing 
peak areas from samples and external standards using HPLC coupled to 
fluorescence detection. A 10 l sample underwent pre-column derivatization with 
orthophthaladldehdye (OPA) in the presence of 2-mercaptoethanol using a 
Shimadzu LC10AD VP autosampler. Chromatographic separation was achieved 
using a Kinetex XB C-18 (50 x 4.6 mm, 2.6 m; Phenomenex) and a mobile 
phase consisting of 100 mM Na2HPO4, 0.1 mM ethylenediaminetetraacetic acid 
(EDTA), 10% acetonitrile at a pH of 6.04. Glutamate was detected using a 
Shimadzu 10RF-AXL fluorescence detector with an excitation and emission 
wavelength of 320 and 400 nm, respectively. Glutamate content for each sample 
was normalized to total protein in the respective well and depicted as a net 
change from baseline. The data was fit using the Michaelis-Menten equation to 
determine Km and Vmax. 
Rhodamine tracer injection: In order to label NAcc efferent pathways, adult rats 
were anesthetized with ketamine/xylazine and underwent stereotaxic surgery. 
Guide cannula (Plastics One) were implanted into the brain targeting the SN (0°, 
-5.0 mm anterior-posterior, +2.1 mm medial-lateral, -6.1 mm dorsal-ventral) or VP 
(0°, -0.6 mm anterior-posterior, +2.8 mm medial-lateral, -6.3 mm dorsal-ventral). 
Micro-injectors (Plastics One) were inserted into guide cannula and extended at 
least +2.0 mm from the distal aspect of the guide cannula for placement into the 
target structure. Rhodamine fluorescent latex microspheres (300 nl; Lumafluor) 
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were injected into the target region. Animals recovered for at least 2 weeks prior 
to use in experiments.  
Brain slice preparation and electrophysiology: Adult rats were anesthetized 
by isoflurane inhalation and perfused through the aorta with a cold sucrose-
based solution (4–6 °C) containing (in mM): 78 NaCl, 68 sucrose, 26 NaHCO3, 
2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2 and 25 glucose. The brain was 
trimmed and embedded in low-melting-point agarose, and coronal striatal slices 
(200-250 m thick) were cut in the sucrose-based solution (4-6 °C) using a 
vibrating slicer (Leica VT1200s). Slices were initially incubated in the above 
sucrose-based solution at room temperature (30-40 min) and were then 
transferred and stabilized (30 min) in an aCSF solution containing (in mM): 119 
NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 glucose. 
All solutions were saturated with 95% O2 and 5% CO2. Whole-cell recordings 
were made using patch clamp amplifiers (Multiclamp 700B) under infrared-
differential interference contrast optics (Nikon Eclipse FN1 and Olympus 
BX51WI) and a 40x water immersion lens. Data acquisition and analysis were 
performed using DigiData 1440A and 1550B digitizers and analysis software 
pClamp 10 (Molecular Devices). Signals were filtered at 2 kHz and sampled at 10 
kHz. Whole-cell patch-clamp recordings were made from rhodamine bead-
labelled medium spiny neurons (MSNs) in NAcc slices. MSNs were also 
identified visually by their medium-sized, spindle-like cell bodies, large initial axon 
segment, and electrophysiological characteristics as described in our previous 
studies (Liu et al., 2013; Wang et al., 2010). Glass pipettes (4-6 MΩ) were filled 
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with one of the following internal solution (in mM): 130 K-gluconate, 10 KCl, 10 
HEPES, 1 EGTA-Na, 2 Mg-ATP, 0.3 Na-GTP, and 10 Na2-phosphocreatine at pH 
7.2 (with KOH). Neurons were voltage-clamped at −70 mV.  A bipolar tungsten-
stimulating electrode was placed at the prelimbic cortex–NAcc border to 
stimulate afferent cortical fibers. The GABAA receptor blocker picrotoxin (100 μM) 
was freshly prepared and dissolved in aCSF using sonication (∼10 min). For the 
recordings of paired-pulse ratio, two consecutive stimuli with 20-400 ms intervals 
were applied. For the recordings of miniature excitatory postsynaptic currents 
(mEPSCs), the Na+ channel blocker tetrodotoxin (TTX, 0.5 M, Tocris) was 
added to the aCSF solution to block action potentials.  
Physiology Telemetry: Adult rats were implanted intraperitoneally with 
telemetry probes (Mini-Mitter Inc.) to remotely record core body temperature and 
locomotor activity while in their home cage. Temperature and activity data were 
collected every 5 minutes and averaged in 1-hour bins. 
Open Field: Adult rats were placed into an open-field chamber (150 x 100 x 40 
cm) and oriented toward a wall to begin the 15-minute session. The amount of 
time animals spent in the center zone (defined as 15 cm from each wall) and the 
total distance travelled was recorded using video-tracking software (EthoVision). 
Novel Object Recognition: During the first two days, rats underwent five-minute 
habituation sessions, which involved placing the rats in a 50x25cm bedding-free 
chamber outfitted with a camera. On the third day, rats were placed into the 
maze for five minutes to become familiarized with two identical objects that were 
placed in adjacent corners of the chamber. One hour later, rats were placed into 
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the maze for five minutes, which had one “familiar” object and one novel object. 
The time spent interacting (looking/sniffing/climbing) with each object was 
recorded during each session on the third day. The placement and identity of 
each object were randomized to control for object and spatial preference. 
Pavlovian Conditioned Approach (PCA) and Omission testing: Adult WT and 
MSxc rats were subjected to an PCA (also known as autoshaping) paradigm 
using touch screen operant chambers (Campden Instruments) (Horner et al., 
2013). Briefly, rats were food deprived to approximately 90% of their ad libitum 
mass and handled daily for a week prior to training. On the first day of training, 
animals were habituated to the chambers for 20 minutes with 20 chocolate 
flavored sucrose pellets placed in the reward delivery tray. If the subject 
consumed all of the pellets, they progressed to the second phase of habituation 
which entailed a 30-minute training session whereby following a variable intertrial 
interval (0-30s) a reward is delivered in the tray concurrent with a tray light and a 
1 second 3 KHz sound. If 40 trials are completed, i.e. 40 rewards consumed, the 
subject progressed to PCA training. PCA training entailed five days of 20 
presentations of CS+ and CS- for a total of 40 total trials. Cues were presented 
when both a variable intertrial interval had passed and the infrared beam in the 
back of the chamber was broken. Cues were presented for 10s and if CS+ was 
presented, cessation was immediately followed by reward delivery with 
concurrent tray light and a 1 second 3 KHz sound. Omission testing was the 
same, however if the rat approached CS+ when it was presented, a reward 
would not be delivered.  
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Fear Blocking and Extinction: Adult rats were trained using a within-subjects 
Kamin fear blocking design (Furlong, Cole, Hamlin, & McNally, 2010). This 
design consisted of four stages across 5 consecutive days: stimulus pre-
exposure (Stage 0), fear conditioning (Stage 1; 2 days), blocking (Stage 2), and 
testing (Stage 3).  Two 30-second auditory cues and two 30-second visual cues 
were used in this experiment: CSA, constant cue-light illumination; CSB, 72-dB 
white noise; CSC, 1-Hz flashing cue-light; CSD, 72-dB 6-kHz tone.  Chambers 
used for training (Stages 0-2) and testing (Stage 3) differed in texture and odor. 
In each session, rats were acclimated to the chamber for 120 sec before stimulus 
presentation (Baseline period). The inter-trial interval was 60 sec in Stages 0 and 
3 and 240 ± 20 sec in Stages 1 and 2. During Stage 0, rats were presented with 
each of the four CSs twice in a pseudorandom order. During Stage 1, rats 
received four presentations of Cue-A co-terminating with a 1-sec foot-shock 
unconditional stimulus (UCS; 0.5 mA) on each of two days. During Stage 2, rats 
received alternating presentations (2 each) of compound cues AB and CD, co-
terminating with the UCS. During Stage 3, rats were briefly returned to the 
training chamber for 10 minutes in the absence of stimuli to assess contextual 
fear. Two hours later, rats were tested in a novel chamber for fear to Cue-B and 
Cue-D in the absence of foot shock (Stage 3) with each stimulus being presented 
four times.  At least seven days following the completion of the fear blocking 
experiment, all rats received an extinction session in the testing chamber. This 
session consisted of 40 unreinforced presentations of Cue-A (30 sec) with an 
inter-trial interval of 60s. The following day, rats were tested for their extinction 
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memory; they were again placed in the extinction chamber and received 8 
unreinforced CSAs. Freezing was defined as the cessation of all movement 
except that needed for respiration and was used as the measure of conditional 
fear during all training and testing sessions(Fanselow & Bolles, 1979). Freezing 
was scored automatically using FreezeScan 2.0 (CleverSys).   
Attentional Set Shifting: Adult rats were food-restricted to 90% of their ad 
libitum body mass for one week. Next, rats were habituated to a four-arm cross 
maze (60 x 20 x 12 cm). For each of the three test sessions, rats were run in 
blocks of 12 trials. For each trial, only three of the four arms were made 
accessible by blocking the fourth arm, thereby creating a T shaped-maze. In this 
configuration, one arm was used as a starting chamber; the arms to the left and 
right of the starting location were used as choice arms. Each of the choice arms 
had a small divider at the distal end to prevent subjects from visually identifying 
which choice arm contained a sucrose pellet. On each of the three test sessions, 
a visual cue (a laminated paper with black and white stripes) was placed in one 
of the choice arms. Following the completion of 12 trials, the configuration of the 
maze rotated such that the arms representing the starting and choice arms could 
be adjusted, thereby minimizing the utility of spatial cues outside the maze.  
Testing continued until the subjects successfully identified the baited arm in ten 
consecutive sessions. On the first daily test session, rats needed to acquire a 
simple visual discrimination to learn that the placement of the sucrose pellet was 
indicated by the placement of the visual cue. On the second daily test session, 
rats were required to utilize an extradimensional shift since the location of the 
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sucrose pellet was indicated by a directional cue (e.g., always turn right or 
always turn left) rather than a visual cue (which now indicated the location of the 
sucrose pellet at chance levels). On the third day, rats were required to display 
reversal learning since the solution involved a directional cue that was opposite 
to that of day 2. Perseverative errors were calculated on days 2 and 3 and 
represented errors due to rats’ applying the prior day’s strategy. Regressive 
errors represented mistakes occurring after identification of the trial strategy (i.e., 
at least 75% correct within a block of 8 trials) but prior to achieving the trial 
criterion (10 consecutive test trials).  
Cocaine Self-Administration and Reinstatement: Adult rats were trained to 
self-administer cocaine (0.5 mg/kg/inf, IV; 2 hr/day) or saline under a fixed-ratio 
one schedule of reinforcement for 12 daily sessions (Madayag et al., 2010). Rats 
then underwent a seven-day abstinence period, followed by extinction training 
sessions, which were identical to the self-administration sessions except lever 
presses resulted in saline infusions. Once rats met the extinction criterion of 
fewer than 15 presses/day, reinstatement testing was conducted. Reinstatement 
testing involved pretreatment with a low dose of cocaine (3 mg/kg, IP) ten 
minutes prior to testing and recording lever pressing for 2 hours.      
Statistical Analysis: Investigators were blinded to genotype for all behavioral 
procedures. All data are presented as means + standard error of the mean. 
Analyses of data sets comprised of only 2 groups were analyzed using two-tailed 
Student’s t-test or the Kolmogorov-Smirnov test (K-S test) for nonparametric 
analyses. Analyses of data sets comprised of three or more groups were 
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analyzed using analysis of variance with Tukey post hoc test. To calculate PCA 





The frequency and amplitude of mEPSCs were calculated for 3-5 min of 
recordings. The analysis of mEPSCs was performed with cumulative probability 
plots (Van der Kloot, 1991). The paired-pulse ratio (PPR) was calculated by 
dividing the mean amplitude of the second EPSCs by that of the first EPSCs. 
Results were deemed significant at p<0.05. 
RESULTS 
Intriguingly, the xCT subunit of Sxc is a relatively recent adaptation for 
animal species (Lewerenz et al., 2013). Hence, analyzing the degree of 
spontaneous mutations within the xCT sequence over the course of the evolution 
of vertebrate species we could infer its functional importance to these organisms. 
To determine this, a phylogenetic tree was constructed to help infer ancestral 
divergence points based on the conservation of the sequence. The tree reveals a 
pattern of divergence consistent with canonical vertebrate species trees whereby 
the traditional classes (e.g. birds, reptiles, and mammals) form separate clades 
(Figure 2-2A). Intriguingly, primates form their own clade which is suggestive of 
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significant changes to the sequence giving rise to a unique xCT sequence 
relative to other mammals.  
One possibility is that the speciation event giving rise to primate xCT was 
driven by the acquisition of novel kinase regulatory sites which could change its 
function. Thus, the sequence was scanned for consensus phosphorylation sites 
which revealed three candidate regions (Figure 2-2B). First, we detected serine 
residue 26 (S26, CaMKII/MSK1 site) and found it to be present in 100% of the 
primates analyzed but only in 45% of non-primate mammals. Next, S481 
(CaMKII/MSK1 site) is only present in 79% non-primate mammals and 100% of 
primates. Last, S185 (GSK3-β site) was present in 92% of vertebrate species. 
This suggests that novel regulatory sites on the xCT sequence were acquired 
during vertebrate evolution and may have given rise to speciation events or 
provided an adaptive advantage to the species that acquired them. In the case of 
humans and other animals, this could include more complex signaling leading to 
more complex cognition or behavior.  
Considering the acquisition of these regulatory sites, we next asked 
whether there was evidence of the xCT sequence evolving under the influence of 
positive or negative selective pressure. Positive selective pressure favors rapid 
genetic changes that provide an adaptive advantage whereas negative selective 






population through a reduction in fitness i.e. acquisition of maladaptive traits (Eric 
J. Vallender & Lahn, 2004). We hypothesized that the regulatory sites may have 
Figure 2-2: Phylogenetic analysis of vertebrate xCT. A, Phylogenetic tree illustrating the 
xCT protein coding sequence relationship across 115 vertebrate species. Major ancestral 
divergence points are evidenced by branch points (all greater than 70 bootstrap). B, The 
percent of species within vertebrate classes that express designated xCT residues targeted by 
their respective kinase; in order from left to right S26, S481, S185. C, Data depicts the degree 
of non-synonymous (dNS) to synonymous mutations (dS; dN-dS) across the xCT sequence. 
CaMKII, Ca2+/calmodulin-dependent protein kinase II; MSK1, mitogen and stress activated 
kinase 1; GSK3-β, glycogen synthase kinase-3 beta. 
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given the species that acquired them an adaptive advantage i.e. were positively 
selected for. To test, a single-likelihood ancestor count (SLAC) analysis was 
used to ascertain the degree of selective pressures driving these sequence 
changes across vertebrate evolution (Kosakovsky Pond & Frost, 2005). This 
analysis revealed that 395/564 (70%) of codons analyzed displayed a 
significantly higher degree of nucleotide mutations that did not alter the amino 
acid sequence (degree of synonymous mutations; dS) than mutations that did 
alter the amino acid sequence (degree of non-synonymous mutations; dNS; 
p<0.05; Figure 2-2C). There was no evidence for positive selective pressure in 
the xCT sequence (0/564, p>0.05). The regulatory sites S185 and S481 were 
under significant negative selective pressure (p<0.05) whereas S26 trended 
toward negative selective pressure (p=0.08). These findings suggest that S26, 
S185, and S481 did not provide an adaptive advantage to species that gained 
them, rather their acquisition was rapidly stabilized and resisted further change. 
Thus, xCT largely evolved under negative selection whereby changes to the 
sequence would likely produce an organism with maladaptive traits. Collectively, 
these data suggest that the phylogenetic signature of xCT indicates it was an 
essential protein to vertebrate species. 
Having established the phylogenetic importance of xCT to vertebrates, we 
next sought to further strengthen our understanding of the cellular expression 
profile of xCT. Models of glutamate signaling depict Sxc as an astrocytic 
mechanism, but the in vivo support for this is limited (Ottestad-Hansen et al., 





labeled astrocytes from adult NAcc tissue via FACS in order to quantify xCT 
expression in these cells (Figure 2-3B). The NAcc was chosen for our molecular 
and cellular experiments since this subcortical structure integrates inputs from 
throughout the brain and is consequently an essential nucleus for cognitive 
processing (Floresco, Ghods-Sharifi, Vexelman, & Magyar, 2006; Svensson & 
Ahlenius, 1983). Furthermore, glutamate signaling in this structure relies on Sxc 
activity (Baker, McFarland, Lake, Shen, Toda, et al., 2003; Baker et al., 2002; M. 
M. Moran, McFarland, Melendez, Kalivas, & Seamans, 2005). Gross 
fluorescence microscopy demonstrates eGFP expression throughout the brain 
(Figure 2-3A). QPCR revealed a lack of NeuN expression in GFP+ cells. 
Figure 2-3. xCT is expressed by GFAP positive cells in the NAcc.  
A, Fluorescence photomicrograph of GFP expression in the rat brain. B, The transgene 
used to fluorescently label-astrocytes in GFAP:Lck-eGFP rats. C, Levels of mRNA for the 
neuronal control gene NeuN, the astrocytic control gene GFAP, and xCT in FACS-sorted 




Additionally, GFAP and xCT expression was significantly higher in GFP+ cells 
relative to GFP- (Figure 2-3C; n=4/genotype: GFAP, t6=5.79, p<0.05; xCT, 
t6=4.01, p<0.05). These data demonstrate that GFAP positive cells, astrocytes, 
are the predominant cell type in the NAcc that expresses xCT. 
Given the phylogenetic significance and the expression of xCT in 
astrocytes, we next sought to determine the physiological and behavioral impact  
of mutating xCT in a mammalian system. We hypothesized that this would 
produce an animal with maladaptive traits. The MSxc rat was developed using 
Zinc-finger nuclease technology which yielded rats that lacked xCT protein and 
mRNA (Figure 2-4A-B). Next, an in vitro cystine-evoked glutamate release assay 
was conducted to test if Sxc was functional. This revealed that cystine uptake 
significantly increased extracellular glutamate in WT but not MSxc astrocytes 
(Figure 2-4C; cystine, F5,79=1.736, p>0.05; genotype, F1,79 =47.963, p<0.05; 
genotype x cystine, F5,79=2.67, p<0.05). Genotypic effects were present within 
25, 50, 100, and 200 µM cystine (Tukey, p<0.05). Additionally, ex-vivo slices of 
the NAcc from WT and MSxc rats were incubated in 14C-L-cystine in the 
presence or absence of the Sxc inhibitor sulfasalazine (SSZ) to determine if Sxc-
dependent cystine uptake was ablated. We report effects of genotype, SSZ, and 
an interaction between these variables (Figure 2-4D; n=10-12 per 
genotype/treatment; genotype, F1,42=54.392, p<0.05; SSZ, F1,42=53.221, p<0.05; 






genotype within vehicle and an effect of treatment within WT (Tukey, p<0.05). 
These data demonstrate that Sxc is functionally knocked out in MSxc rats. 
To investigate the physiological and behavioral impact of loss of Sxc 
function we first utilized paradigms that would test for genotypic differences in 
physiological telemetry, development, exploratory behavior, and simple 
associative learning which would indicate the presence of maladaptive traits. We 
report a lack of a genotypic effect on postnatal growth rate (Figure 2-5A; n=25-
28/genotype; effect of genotype F1,51=0.33, p>0.05; week: F4,204=22.18, p<0.001; 
genotype x time: F4,204=4.20, p<0.001; p> 0.05 when comparing genotype at 
each week), diurnal core body temperature (Figure 2-5B; n=7-8/genotype; 
genotype x time F120,1560=0.952, p>0.05; genotype F1,13=0.113, p>0.05; time 
F120,1560=51.133, p<0.001), and home cage locomotor activity (Figure 2-5C; 
n=12/genotype; genotype x day F7,91=0.458, p>0.05; genotype F1,13=0.331,  
Figure 2-4: Validation of a Sxc-deficient rat model. A-B, xCT protein and mRNA 
expression, respectively, in NAcc tissue samples obtained from WT and MSxc rats. C, 
Cystine-evoked glutamate release was in cultured striatal astrocytes generated from PD3 WT 
and MSxc tissue. D, Radiolabeled cystine uptake in NAcc ex-vivo slices from WT and MSxc 
rats in the presence or absence of the xCT inhibitor sulfasalazine (SSZ). Two-way ANOVA, 
Tukey test; C, * effect of genotype within given cystine, p<0.05; D, * effect of treatment within 
genotype; + effect of genotype within treatment, p<0.05. Special thanks to Dr. Jeffrey 





p>0.05; day F7,91=2.759, p<0.05). Additionally, there were no genotypic effects 
on total distance or time spent in the center of an open field arena (Figure 2-5D; 
n=12/genotype; total distance t22=1.60, p>0.05; center time t22=0.306, p>0.05) or 
novel object recognition (Figure 2-5E; n=9/genotype; t16=0.216, p>.05). 
Furthermore, MSxc rats did not differ from WT in trials needed to reach 
completion criterion when tested in associative operant tasks reinforced with 
sucrose (Figure 2-5F; n=19-31/genotype; t48=0.84, p>.05) or cocaine 
(n=13/genotype; t24=0.903, p>.05). These data demonstrate that MSxc rats do 
Figure 2-5. Loss of Sxc does not produce widespread impairments in physiology or 
behavior. A, MSxc rats did not display developmental deficits in the form of post-weaning 
size or growth rates to adulthood. B, Central regulation of metabolism as reflected by 
absolute or diurnal changes to core body temperature was unaltered in MSxc rats. C-D, 
MSxc rats display normal levels of activity in familiar and novel environments. C, Telemetry 
measures of general activity in the home-cage over a five-day period was not altered by 
genotype. D, Activity levels and time spent in the center zone of a novel environment were 
also similar between WT and MSxc rats. E, Simple recognition memory as assessed by 
comparing time spent with a novel object did not differ between WT and MSxc rats. F, 
Evidence that the capacity to form simple associations was unaltered in MSxc rats also 
involved a lack of a genotypic effect on the number of trials needed to acquire a food or 




not appear to display maladaptive traits in physiology, basic memory tasks, and 
simple associative learning.  
To investigate whether maladaptive disruptions in cognition were present 
in the MSxc rat, we first employed a Pavlovian-conditioned approach (PCA) 
paradigm (Figure 2-6). PCA, also referred to as autoshaping, has been used to 
model the process by which discrete stimuli are learned to be predictive of a 
desired outcome, acquire motivational properties, and subsequently influence 
behavior (Robinson, Yager, Cogan, & Saunders, 2014). The rationale for this 
approach is that PCA allows us to assess the degree of “top-down” versus 
“bottom-up” regulation of behavior i.e. behavior guided by a calculation of 
discriminating relevant stimuli in accordance with previously acquired knowledge 
about the probability of an outcome versus sensory input readily impacting 
behavioral output, respectively (E. K. Miller & Cohen, 2001; Sarter, Givens, & 
Bruno, 2001). In PCA procedures, CS+ (reward-predictive conditioned stimulus) 
approach is viewed as a “bottom-up” driven behavior due to the incentive and 
motivational value placed on CS+ by the subject, even though this behavior is not 
required for reward delivery (Sarter & Phillips, 2018).  
To ascertain the ability for the subjects to learn that the presentation of 
CS+ is predictive of a reward delivery, tray entries, CS approaches and the 
latency to enter were analyzed. A two-way repeated measure ANOVA was used 
to determine genotypic differences, differences across the training session, and 
any interaction between these variables on a within-subject basis. Regarding 





session (F4,68=34.227, p<0.05) with no effect of genotype (F1,68=1.108, p>0.05) 
nor an interaction between these variables (F4,68=1.492, p>0.05). Notably, there 
was an increase in tray entries by sessions 2-5 relative to session 1 (Tukey, 
p<0.05). This increase did not occur to the same extent when CS- was 
presented, as the effect of session was restricted to an escalation between 
session 1 and 4 (Figure 2-7B; genotype, F1,68=0.847, p>0.05; session, 
F4,68=3.465, p<0.05; genotype x session; F4,68=0.563, p>0.05; Tukey, p<0.05). 
Additionally, there was an effect of session on tray entry latency with no effect of 
genotype nor an interaction. (Figure 2-7E; genotype, F1,68=3.965, p>0.05; 
session, F4,68=17.378, p<0.05; genotype x session; F4,36=0.535, p>0.05). By 
sessions 3, 4, and 5, subjects were significantly faster at entering the tray 
(Tukey, p<0.05). Collectively, these data demonstrate that both genotypes were 
able to associate reward delivery in the tray with CS+ and not CS-. 
 
Figure 2-6. Pavlovian conditioned approach experimental design. A, Top- down view of 
the Campden touch screen behavioral chamber. B, Front-view of the behavioral chamber 
with two rectangular screens spanning the floor to ceiling flanking the reward tray. The 
conditioned stimulus (CS) is a large visual X on the screen C, Flowchart for the training 





Next, genotypic differences in CS+ approach behavior, a measure of 
bottom-up regulation of behavior, was analyzed. Regarding CS+ approaches 
during presentation (Figure 2-7C), we report main effects of session (F4,68=4.539, 
p<0.05) and genotype (F1,68=5.162, p<0.05) with a significant interaction between 
these variables (F4,68=6.571, p<0.05). Notably, there was an increase in CS+ 
approaches among MSxc rats in sessions 3, 4, and 5 relative to session 1 in 
addition to an effect of genotype relative to WT within sessions 3-5 (Tukey, 
Figure 2-7: Loss of Sxc does not alter associative learning but increases CS+ approach 
behavior during PCA training. A-B, Data depicts total reward tray entries during the 
presentation of CS+ or CS- respectively. C-D, Total approaches toward the screen during the 
presentation of CS+ or CS- respectively. E, Amount of time prior to the first reward tray entry 
when CS+ is presented. F, Latency to approach CS+ during presentation. Two-way repeated 
measure ANOVA; # effect of session relative to session 1, + effect of genotype independent 
of session, * effect of genotype within the given session p<0.05. 
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p<0.05). Regarding CS- approaches, there were main effects of session (Figure 
2-7D; F4,68=4.345, p>0.05) but not genotype (F1,68=0.247, p>0.05) with an 
interaction between these variables (F4,68=2.656, p>0.05). Intriguingly, WT rats 
increased their approaches toward CS- by sessions 3-5 relative to session 1 and 
WT rats approached CS- more than MSxc rats during session 1 (Tukey, p<0.05) 
Furthermore, there was an effect of session on CS+ approach latency with no 
effect of genotype nor an interaction (Figure 2-7F; Two-way ANOVA; genotype, 
F1,79=1.113, p>0.05; session, F4,79=2.837, p<0.05; genotype x session; 
F4,79=0.653, p>0.05). Rats approached CS+ more rapidly by sessions 4 and 5 
relative to session 1 (Tukey, p<0.05). Notably, rats that did not approach CS+ 
had no latency measurement so they were excluded from this specific analysis. 
These data demonstrate that MSxc rats displayed increased CS+ approach 
behavior as PCA training progressed yet both genotypes approached CS+ faster 
as training progressed. 
Having established genotypic differences in CS+ approach during the PCA 
training sessions, rats were then tested in an omission phase whereby CS+ 
approach behavior prevented the delivery of a reward. Omission is meant to test 
whether the CS+ approach behavior can be inhibited due to negative 
punishment, a form of top-down cognitive control (E. K. Miller, 2000). We 
hypothesized that punishment would likely impact CS+ approach but not tray 
entries. Indeed, tray entries when CS+ was presented (Figure 2-8A), revealed a 
main effect of session (F4,68=4.780, p<0.05) with no effect of genotype 
(F1,68=3.429, p>0.05) nor an interaction between these variables (F4,68=0.0296, 
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p>0.05). Notably, there was an escalation in tray entries by sessions 4 and 5 
relative to session 1 (Tukey, p<0.05). A similar phenomenon occurred when CS- 
was presented (Figure 2-8B; genotype, F1,68=1.609, p>0.05; session, F4,68=3.582, 
p<0.05; genotype x session; F4,68=0.155, p>0.05) with a small escalation in tray 
entries by sessions 4 and 5 relative to session 1. Regarding CS+ approaches 
during presentation (Figure 2-8C), we report a main effect of session 
(F4,68=7.633, p<0.05) an effect of genotype (F1,68=6.187, p<0.05) with no 
significant interaction between these variables (F4,68=1.707, p>0.05). Notably, 
there was a reduction in CS+ approaches independent of genotype in sessions 3, 
4 and 5 relative to session 1 (Tukey; p<0.05). This did not occur with CS- 
approaches (Figure 2-8D; genotype, F1,68=0.523, p>0.05; session, F4,68=0.870, 
p>0.05; genotype x session; F4,68=0.723, p>0.05). The net effect of this 
prolonged CS+ approach behavior in MSxc rats was a greater number of missed 
rewards across all sessions (Figure 2-8E; genotype, F1,68=5.859, p<0.05; 
session, F4,68=8.317, p<0.05; genotype x session; F4,68=0.832, p>0.05). The 
number of missed rewards decreased by sessions 3,4, and 5 relative to session 
1 (Tukey, p<0.05). Furthermore, the cumulative number of missed rewards 
during omission testing was greater in MSxc rats (Figure 2-8E; t-test, t17=-2.421, 
p<0.05). These data demonstrate that both genotypes continue to escalate their 
tray entries and reduce approaches during CS+ presentation over the course of 
omission testing, but MSxc rats have a prolonged increase in CS+ approach 






 Alternatively, PCA data can be expressed using the PCA score which 
incorporates all dependent variables described so far (see methods for 
description of the score calculation). The PCA score is on a scale of +1 to -1 
which correspond to behavior being predominantly directed toward CS+ or the 
reward tray respectively. These phenotypes are referred to as sign- and goal-
tracking respectively (Meyer et al., 2012). During PCA training, there was an  
Figure 2-8: CS+ approach behavior is maintained even when punished in MSxc rats 
during omission testing. A-B, Data depicts total reward tray entries during the presentation 
of CS+ or CS- respectively. C-D, Data depicts total cue approaches during the presentation of 
CS+ or CS- respectively. E, Data depicts the number of rewards missed during the omission 
testing sessions with a cumulative count presented in F. Two-way repeated measure ANOVA; 
# effect of session relative to session 1, p<0.05; + effect of genotype independent of session, 
p<0.05. *students t-test; p<0.05. Two-way repeated measure ANOVA; # effect of session 






effect of session (Figure 2-9A; F4,68=3.076, p<0.05) genotype (F1,68=5.925, 
p<0.05) and a significant interaction between these variables (F4,36=3.147, 
p<0.05). By session 3,4, and 5, MSxc rats had a significantly higher PCA score 
relative to WT (Tukey, p<0.05). Additionally, the PCA score of WT rats decreased 
by sessions 4 and 5 relative to session 1 whereas the PCA score of MSxc rats 
was not impacted by session (Tukey, p<0.05). During omission, there were 
effects of session and genotype with no interaction between these variables 
(Figure 2-9B; genotype, F1,68=4.899, p<0.05; session, F4,68=4.026, p<0.05; 
genotype x session; F4,68=1.183, p>0.05). Indeed, PCA score increased by 
session 5 relative to session 1 independent of genotype (Tukey, p<0.05). These 
data demonstrate that the PCA score for MSxc rats is shifted upward relative to 
WT which corresponds to greater CS+ directed behaviors. Collectively, the PCA 
and omission data demonstrate genotypic differences in stimulus-associated 
Figure 2-9: Loss of Sxc produces an upward shift in PCA score. A-B, Data depicts PCA 
scores during PCA training and omission testing, respectively. Please see methods for PCA 
score calculation. Two-way repeated measure ANOVA; * effect of genotype within the given 
session, p<0.05; + effect of genotype independent of session, p<0.05; # effect of session 
relative to session 1 p<0.05. 
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behavior which persists even when rewards are lost which is indicative of a 
disruption in executive control over behavior. 
One interpretation of the prolonged CS+ approach behavior in MSxc rats 
during omission testing is that MSxc rats have impaired behavioral flexibility. To 
test, we utilized a maze-based attentional set-shifting paradigm to test MSxc rats’ 
ability to flexibly adapt behavioral strategy to obtain a sucrose reward (Figure 2-
10A, n=6-7/genotype). The impact of genotype depended on the trial (Figure 2-
10B; Two-way ANOVA, genotype x phase: F2,22=3.78, p<0.05). Consistent with 
previous data, there was no effect of genotype during the simple discrimination 
phase (t11=0.348, p>0.05).  However, MSxc rats needed significantly more trials 
to reach criterion during the extra-dimensional shift phase (t11=0.3.83, p<0.05). 
and intra-dimensional shift phase (t11=2.96, p<0.05). This phenomenon results 
from a significant increase in incidence of perseverative (Figure 2-10C; t11=3.39, 
p<0.01) but not regressive errors (Figure 2-10D; t11=0.86, p>0.05) made by MSxc 
rats during the second and third phase of testing. These data demonstrate that 
MSxc rats display behavioral inflexibility independent of disruptions in simple  
associative learning due to perseveration of a behavioral strategy that is no 
longer reinforced. 
To further examine the degree of disrupted executive function in MSxc 
rats, we employed a Kamin fear blocking paradigm which assesses rats’ capacity 







n=8/genotype). This procedure creates conditions whereby an association 
between a novel cue (Cue-B) and shock is prevented or “blocked” by co- 
presentation of a previously established predictor of shock (Cue-A). Hence, the 
presence of Cue-A eliminates the predictive value of the novel cue (Cue-B).  
When exposed to Cue-B on the test day, WT rats did not display an increase 
from baseline in conditioned freezing but did freeze in response to a novel Cue-D 
(Figure 2-11B; F2,14=10.73, p<0.001; Tukey HSD versus baseline, p<0.05). In  
Figure 2-10. Loss of Sxc activity impairs cognitive flexibility A, A schematic illustrating 
the experimental stages of the attentional set-shifting paradigm in which the number of trials 
needed to solve a novel maze task is assessed. B, The number of trials required to meet 
criteria for each of the three test sessions is depicted. The impact of genotype depended on 
the trial. There was no effect of genotype on day 1, which required subjects to use stimulus 
discrimination (SD) to identify the arm of the maze baited with food. MSxc rats needed 
significantly more trials to reach criterion on day 2, which required an extradimensional shift 
(EDS) to solve the task. MSxc rats also needed more trials to reach criterion on day 3, which 
required an intra-dimensional shift (IDS) to solve the task. C, On days 2 and 3, MSxc rats 
displayed more perseverative errors. D, The number of regressive errors on days 2 and 3 did 





contrast, MSxc rats displayed a lack of Kamin blocking since these rats displayed 
a similar amount of conditioned freezing to Cue-B and Cue-D (Figure 2-11B; 
F2,14=6.94, p<0.01; Tukey versus baseline, p<0.05). This effect was not due to 
genotypic differences in the acquisition (Figure 2-11C; genotype x trial: 




Figure 2-11. Loss of Sxc activity impairs the gating of associative processes. A, 
Schematic illustrating the experimental stages of the Kamin blocking procedure. The 
procedures are designed so that the co-presentation of an established shock-predictive cue 
(Cue-A) will block a novel cue (Cue-B; “blocked stimulus”) from being paired with shock 
during Stage 2 and, therefore, from eliciting conditioned freezing on the test day. B, Freezing 
behavior during the test day as measured during baseline (BL) or following exposure to Cue-
B or Cue-D. WT rats display conditioned freezing to Cue-D, but not to the “blocked” stimulus, 
Cue-B. MSxc rats displayed similar levels of freezing to Cue-D and Cue-B, indicating impaired 
Kamin blocking. C-D, Freezing behavior during the acquisition and extinction of fear 
conditioning. Two-way ANOVA; *effect of cue relative to baseline Tukey p<0.05. Special 





conditioning (Figure 2-11D; F5,70=0.77, p>0.05; genotype main effect F1,14=0.52, 
p>0.05) or in the retention of extinction memories (Figure 2-11D; F1,14=0.37,  
p>0.05). These data lend further evidence towards MSxc rats having executive 
dysfunction. 
The maladaptive associative learning and inflexible, perseverative patterns of 
behavior seen in MSxc rats are observed in a variety of human disorders 
including substance abuse (Ersche, Roiser, Robbins, & Sahakian, 2008; Keiflin & 
Janak, 2015; Steinberg et al., 2013). To determine whether a loss of Sxc activity 
Figure 2-12: Loss of Sxc increases relapse vulnerability. A, Diagram depicting the 
operant chamber set up and experimental design of the cocaine self-administration model. 
B, Data depicts number of infusions of cocaine received during the maintenance phase 
(0.5mg/kg/infusion). C, Extinction training phase whereby lever presses no longer yielded a 
cocaine infusion D, Reinstatement test phase whereby a subthreshold dose of cocaine was 
delivered by the experimenter (3 mg/kg I.P). Two-way ANOVA; * Effect of treatment within 
genotype; +Effect of genotype within treatment, Tukey p<0.05. 
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impacts reinforced and non-reinforced drug-seeking, we employed a cocaine 
self-administration paradigm which includes three main phases: self-
administration, extinction of lever responding, and reinstatement of seeking 
(Figure 2-12A). Importantly, rates of cocaine self-administration did not differ 
across genotype (Figure 2-12B; genotype x session: F11,264=0.816, p>0.05; 
genotype: F1,24=0.052, p>0.05). Additionally, responding under extinction 
conditions, whereby the lever was no longer reinforced with cocaine, did not 
differ across genotype (Figure 2-12C; genotype x session: F1,24=0.611, p>0.05; 
genotype: F1,24=0.005, p>0.05). However, during the cocaine-primed 
reinstatement test, MSxc rats displayed higher levels of responding relative to 
their last extinction trial that otherwise did not reinstate responding in WT rats 
(Figure 2-12D; t11=3.26, p<0.05 WT versus MSxc during cocaine test). These 
data demonstrate that loss of Sxc function does not alter self-administration of 
cocaine or extinction learning. However, MSxc rats display increased 
vulnerability for relapse to an otherwise sub-threshold dose of cocaine which 
suggests a lack of executive control over a behavior that no longer elicits a 
rewarding outcome. 
Having established that loss of Sxc impairs executive function, we next 
sought to determine how loss of Sxc impacts the tripartite synapse which may in 
part help illuminate the observed cognitive dysfunction. In order to ascertain 
molecular disruptions in the glutamate system of MSxc rats, we chose a key 
component from each compartment of the tripartite synapse that Sxc has been 





synaptic domain. In the pre-synaptic domain, we found no difference in group 2 
metabotropic glutamate receptor expression (mGluR2/3; Figure 2-13A; 
n=8/genotype; t14=0.967, p>0.05) which corresponded to no change in pre-
synaptic release probability as measured by paired-pulse ratio (Figure 2-13A). 
Additionally, GLT-1 expression was unchanged in MSxc rats (Figure 2-13B; 
n=8/genotype; t14=0.26, p>0.05). However, when EAAT function was measured 
Figure 2-13. Loss of Sxc alters components of the tripartite synapse. A, NAc protein 
levels of the presynaptic protein mGluR2/3 and paired-pulse ratio. B, NAc protein levels of the 
astrocytic glutamate transporter GLT-1 and 3H-D-aspartate uptake in both NAcc tissue (ex 
vivo) and cultured astrocytes (in vitro), as a measure of excitatory amino acid transporter 
function. C, Western blots of the postsynaptic protein GluA1 and GluA1 phosphorylated at 
threonine 840 (GluA1pT840). * p<0.05, t-test. 
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by 3H-D-Aspartate uptake, MSxc NAcc tissue had significantly lower uptake 
relative to WT (Figure 2-13B; n=15-18/genotype; t31=2.69, p<0.05). This 
disruption was also present in cultured astrocytes (Figure 2-13B; n=11-
12/genotype; t21=6.61, p<0.05). Furthermore, post-synaptic changes were also 
investigated; total GluA1 expression was unchanged in MSxc rats (Figure 2-13C; 
n=7-8/genotype; t14=0.967, p>0.05) but there was a significant increase in GluA1 
phosphorylation at threonine residue 840 (pT840; Figure 2-13C; t13=2.93, 
p<0.05). These data demonstrate the presence of impaired EAAT function and 
GluA1 hyper-phosphorylation in the NAcc of MSxc rats independent of changes 
in pre-synaptic release of glutamate.  
Given the molecular and functional changes in GluA1 and EAATs, we 
hypothesized that excitatory output from the NAcc would be increased in MSxc 
rats. Miniature excitatory post-synaptic currents (mEPSCs) were measured from 
medium spiny neurons (MSNs n=15-17/genotype) projecting to the substantia 
nigra (SN; Figure 2-14A,C) and ventral pallidum (VP; Figure 2-14B,D). The 
frequency (t26=2.7, p<0.05) and amplitude (t26=2.35, p<0.05) of mEPSCs were 
increased in MSxc SN MSNs which correlated with a leftward shift in intervals 
and rightward shift in amplitude cumulative probability plots. Additionally, 
mEPSCs were unaltered in VP MSNs (Frequency, t30=0.01, p>0.05; amplitude, 
t31=0.52, p>0.05).  These data suggest that loss of Sxc produces an 
enhancement of synaptic strength in an efferent specific manner and 
consequently highlight a role for Sxc in regulating AMPAR function and gating 








The purpose of these studies was to test the possibility that the acquisition 
of Sxc was a key event in achieving the signaling complexity needed for 
executive function and cognition in vertebrate species. We hypothesized that 
disrupting Sxc function would be sufficient to disrupt glutamate 
neurotransmission and produce a rat with maladaptive behavioral traits. We 
found that eliminating Sxc increased the likelihood that environmental stimuli, 
and previously learned associations about them, would be more likely to elicit an 
 
Figure 2-14.  Loss of Sxc 
enhances basal excitatory 
neurotransmission. A, 
Diagram depicting rhodamine 
latex microsphere injection 
targeting the substantia nigra 
pars compacta (SNpc); 
center- expression of 
rhodamine fluorescent cells in 
the NAcc; right- validation of 
the injection site. C, Left- 
diagram depicting rhodamine 
latex microsphere injection 
targeting the globus pallidus 
(GP); center- rhodamine 
fluorescent cells in the NAcc; 
right- validation of the 
injection site, hitting the 
majority of the GP. B, Sample 
traces from WT and MSxc 
SNpc projecting and D, GP 
projecting MSNs. (Right) 
Cumulative probability plots 
for inter-event intervals and 
amplitude of mEPSCs 
recorded from the respective 
efferent. * T-test p<0.05. 
Special thanks to Dr. Qing-




inappropriate behavioral response. Despite altering behavioral phenotypes in 
PCA, set shifting, fear blocking, and cocaine reinstatement tasks, the loss of Sxc 
did not disrupt exploratory behavior, basic learning and memory, or general 
physiology. This suggests that the role of Sxc in cognition is discrete and 
restricted to executive functions such as reversal learning, attentional gating, and 
behavioral control. This degree of cognitive dysfunction in a natural environment 
would likely put MSxc rats at a significant disadvantage, making them 
maladapted to their environment.  
Furthermore, loss of Sxc produced discrete disruptions in excitatory 
signaling in the NAcc. We found that loss of Sxc broadly impaired EAAT function 
in astrocytes. Additionally, AMPAR were hyperphosphorylated at residue T840 
which corresponded to an enhancement in mEPSCs in the direct but not indirect 
pathway from the NAcc. Notably, these changes were independent of any 
change in pre-synaptic glutamate release. The significance of this pathway 
specific enhancement is evidenced by the direct pathway being important for 
driving motivated behavioral responses (Bromberg-Martin, Matsumoto, & 
Hikosaka, 2010; Lobo et al., 2010). This may in part explain why cognitive 
dysfunction was observed in MSxc rats, due to an inability to effectively gate 
excitatory output in this pathway. However, more work will be needed to 
determine if dampening this pathway would be sufficient to rescue the cognitive 
deficits. 
These findings reveal that the existence of evolutionarily new glutamate-
release mechanisms could enable the isolation and therapeutic targeting of 
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signaling needed for specialized domains of brain function, such as cognition. 
Indeed, there is growing evidence that compounds that increase Sxc activity 
such as n-acetylcysteine have significant therapeutic potential in pre-clinical and 
clinical studies of cognitive disorders such as drug addiction, binge eating 
disorder, trichotillomania, and obsessive compulsive disorder (Amen et al., 2011; 
J. E. Grant, Odlaug, & Kim, 2009; Hurley et al., 2016; Oliver et al., 2015; Tomko 
et al., 2018). Importantly, these studies highlight the efficacy of n-acetylcysteine 
and its tolerability in patients due to a lack of significant side effects which 
supports the discrete role of Sxc in brain function and behavior, thus making it an 
excellent therapeutic target. 
The potential for Sxc to confer important benefits to brain complexity and 
behavioral capabilities should be evident in the evolutionary history of 
Slc7a11/xCT. The Sxc-subunit xCT first appeared some point after the 
divergence of protostomes and deuterostomes (Lewerenz et al., 2013), which 
indicates that Sxc is a relatively newer adaptation in animals. Our key findings 
from our phylogenetic analysis were that the majority of the xCT protein coding 
sequence was under significant negative selective pressure in vertebrates, and 
the sequence has gained novel kinase regulatory sites. Specifically, our SLAC 
analysis, which detects amino acids that were under selective pressure, found 
that 70% of the amino acids had a greater degree of synonymous than non-
synonymous mutations occurring within their codons. This means that while 
mutations did occur, they were more likely to encode the same amino acid. This 
demonstrates that selective pressures resisted changes in the sequence, such 
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that if a non-synonymous mutation were to occur, it would be rapidly removed 
from the gene pool through purifying selection. In other words, the mutation 
would make the organism maladapted to their environment. Importantly, the 
SLAC analysis did not detect evidence of positive selective pressure, e.g. a gain 
of an adaptive mutation, in the xCT sequence.  
While there were no sites under positive selective pressure, further 
inspection of the sequence revealed the gain of regulatory sites. The three sites 
were S26, S185, and S481 and have varying degrees of conservation in 
vertebrates. For example, S26 is more represented in primates than in birds, 
reptiles, fish, or other mammals whereas S481 is unique to mammals. This 
suggests these sites were involved in speciation, perhaps through providing 
some functional advantage. However, our SLAC analysis did not conclude that 
these regulatory sites were positively selected for. While advantageous 
mutations are of interest, detecting them is difficult considering that synonymous 
mutations and negative selection are the predominant evolutionary forces (M. 
Kimura, 1968; Motoo Kimura, 1983; Kreitman, 2000). Given this, there are two 
principle interpretations that can be drawn about the significance of the 
regulatory sites. First, our statistical methods used to determine selective 
pressure are limited by the available sequence data. While we analyzed 115 
vertebrate species, there are many more species whose xCT sequence is not 
known. By adding more data, it is possible that sites under positive selection 
would arise. On the other hand, acquisition of these sites may have been due to 
random genetic drift that just happened to become stabilized within certain 
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species. With either interpretation, further work is needed to elucidate the 
biological relevance of these novel regulatory sites in xCT. 
Collectively, the phylogenetic signature of xCT suggests it is a 
fundamental protein to vertebrates; organisms without it have maladaptive 
cognitive traits. While our phylogenetic analysis failed to find evidence for 
mutations that provided an adaptive advantage, this approach still revealed novel 
regulatory sites that were gained during vertebrate evolution. If we can 
characterize the functional relevance of these regulatory sites, we will be able to 
understand their contribution to cognitive ability. Using this information, we could 
investigate the possibility that polymorphisms that alter these sites make humans 
more susceptible to cognitive disorders. In support,  the phosphorylation of S26 
has been shown to regulate Sxc function and dysregulation of this site may 
contribute to the psychotomimetic effects of phencyclidine in rats, a pre-clinical 
model of schizophrenia (McClatchy et al., 2016). Thus, these findings are 
consistent with the possibility that disrupted function of evolutionarily new genes 
expressed by astrocytes may underlie cognitive impairments.   
Intriguingly, while xCT itself is a relatively recent adaptation on the 
evolutionary timeline (Lewerenz et al., 2013), its ancestral homologs in 
invertebrates share similar functional characteristics and suggests that it has 
been critical for cognitive processing for millions of years. In support, it is 
accepted that invertebrate species such as c. elegans and drosophila can learn 
conditioned approach responses  and are able to successfully adapt behavior in 
response to changes in the environment to improve survivability (Foley, 
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Marjoram, & Nuzhdin, 2017; Zhao, Khare, Feldman, & Dent, 2003). Importantly, 
they express a putative xCT homolog named genderblind (gb), which has 
approximately 36-45% sequence homology to mammalian xCT and contains the 
essential cystine residue (C158) allowing it to dimerize to 4F2hc (Augustin, 
Grosjean, Chen, Sheng, & Featherstone, 2007). The function of gb is strikingly 
like mammalian xCT. Its function is to maintain extracellular glutamate which 
desensitizes neuronal glutamate receptors and dampens excitatory output. Its 
role in cognitive processing is to regulate how olfactory chemical stimuli influence 
approach behavior. Consequently, drosophila lacking gb more readily engage in 
homosexual mating behaviors due to misinterpretation of sexual olfactory stimuli, 
which is inherently maladaptive (Grosjean, Grillet, Augustin, Ferveur, & 
Featherstone, 2008). Furthermore, deletion of gb is not inherently fatal, which 
suggests that gb/xCT have maintained a discrete role in cognitive processing for 
millions of years. Thus, while xCT is considered a relatively recent adaptation, it 
has maintained some of the functional and qualitative characteristics of its 
ancestral homologs. 
While a narrower manipulation of Sxc such as a conditional knockout in 
adulthood may have been an alternative approach to investigate certain aspects 
of our hypothesis, we felt the global knockout was the only way in which broad 
questions about the role of Sxc in mammalian cognition could be addressed. 
While an argument could be made for the observed cognitive dysfunctions being 
the result of developmental perturbations,  previous work from our lab 
demonstrates that acute pharmacological disruptions in adulthood produced 
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similar deficits in behavioral flexibility to those seen in the MSxc rat (Lutgen et al., 
2014). Additionally, our global knockout approach is similar to what was used to 
explore the functional role of the Dlg orthologs in cognitive processing in mice (S. 
G. Grant, 2016).  Furthermore, If the global knockout approach was not used, we 
would not have learned that loss of Sxc is not inherently fatal and is void of any 
obvious developmental impairments which would be suggestive of it being 
involved in fundamental brain functions that support life, and consequently make 
it a risker therapeutic target. Lastly, because Sxc is present in the amygdala, 
hippocampus, prefrontal cortex and NAcc (Baker, McFarland, Lake, Shen, Tang, 
et al., 2003; Lutgen et al., 2014), which are all brain regions involved in cognitive 
processing, an acute knockdown approach in each region coupled to all of our 
behavioral measures would have been laborious and it does not control for the 
possibility that Sxc dependent signaling in these other brain regions could 
compensate for disruption in another. Thus, our global knockout approach was 
appropriate for the questions we sought to answer, which revealed that Sxc has 
a discrete role in cognition and is not critical for fundamental brain functions that 
sustain life. 
PCA has been used to model the process by which stimuli are learned to 
be predictive of a desired outcome, acquire motivational properties, and 
subsequently influence behavior (Robinson et al., 2014). In canonical models of 
PCA, an operant chamber is outfitted with retractable levers which serve as the 
CS and are predictive of a food reward delivery. Over repeated pairings, the lever 
extension triggers a conditioned approach and appetitive response to the lever 
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as it has become imprinted with the incentive and perhaps emotional value of the 
food reward  (Meyer, Cogan, & Robinson, 2014). A common observation is that 
two distinct behavioral phenotypes emerge during training; sign tracking and goal 
tracking, which correspond to the rats’ propensity to guide appetitive behavior 
towards the CS or towards the reward tray, respectively. These phenotypes are 
characterized by the PCA score, which is on a scale of +1 (sign tracking) to -1 
(goal tracking) with an intermediate phenotype at 0 (Meyer et al., 2012). Over 
repeated training, sign tracking behavior becomes the predominant phenotype, 
with little to no tray entries during the presentation of the CS. A key distinction 
relative to our experiments is the use of a retractable lever rather than a visual 
stimulus as the CS. Notably, our WT rats over the course of training display 
almost a complete lack of CS approach behavior but do increase tray entries 
across training whereas MSxc rats increase CS approach in addition to tray 
entries that persists even when punished for CS approach. The lack of approach 
behavior in WT rats was surprising but it is consistent with reports that 
demonstrate conditioned approach is reduced when the CS cannot be physically 
interacted with (Cleland & Davey, 1983; Meyer et al., 2014). Because of this, our 
ability to observe the degree to which the CS influences behavior in MSxc rats 
relative to WT was enhanced. Furthermore, this suggests that the PCA score and 
the categorization of sign- versus goal-trackers can be unreliable due to it being 
heavily influenced by experimental parameters. 
CS+ approach behavior exhibited by MSxc rats may be indicative of 
inappropriate associative learning and an impairment in executive function. 
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Importantly, reward delivery is not contingent on the rat approaching CS+. It is 
possible that during the initial phases of training, MSxc rats formed an 
inappropriate association between their CS+ approach behavior and reward 
delivery. Given that CS+ approach continued to increase across sessions, it is 
likely that MSxc rats were learning that their approach is what was causing 
reward delivery.  In this way, CS+ approach is viewed as a “bottom-up” driven 
behavior due to the incentive and motivational value placed on CS+ by the 
subject (Sarter et al., 2001; Sarter & Phillips, 2018). When CS+ approach was 
punished during omission, MSxc rats continued to engage the CS+ which is 
indicative of a lack of behavioral control or impaired “top-down” regulation of 
behavior. The prefrontal cortex in particular is necessary when behavior needs to 
be guided or altered by changes in internal or environmental circumstances, such 
as when the probability of an outcome is changing (E. K. Miller & Cohen, 2001). 
These findings have translational validity, as rats that display heightened CS+ 
directed behavior during PCA prefer cocaine over natural rewards when given a 
choice (Tunstall & Kearns, 2015) and are more vulnerable to relapse when 
exposed to drug-associated stimuli (Versaggi, King, & Meyer, 2016). Thus, it was 
not surprising to see that MSxc rats displayed heightened cocaine-primed 
reinstatement.  
Impaired executive function was also observed during the attentional set 
shifting and fear blocking paradigms. During set shifting, the rat must form the 
association that the arm of the maze with a visual stimulus is predictive of 
reward. On subsequent days the rat has to adapt a new strategy to obtain reward 
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(always turn a given direction) as the visual cue is no longer absolutely predictive 
of reward. Because the environmental circumstances and probability of a 
rewarding outcome is changing, the executive centers such as the prefrontal 
cortex are necessary to appropriately guide behavior  (E. K. Miller & Cohen, 
2001). Likewise, for Kamin fear blocking, the executive centers are required 
efficiently direct focal attention toward environmental stimuli that are predictive of 
danger while blocking out ones that are not (Diamond, 2013; Posner & 
DiGirolamo, 1998). Expectedly, WT rats did not show fear to a novel stimulus 
that was co-presented with a stimulus that was previously learned to be 
predictive of danger. On the other hand, MSxc rats did show fear which suggests 
they lack the ability to effectively gate extraneous sensory information. Given our 
behavioral findings, MSxc rats appear to have impaired executive function. As a 
result, environmental stimuli, and previously learned associations about them, 
are more likely to elicit an inappropriate behavioral response in MSxc rats. 
Importantly, MSxc rats are able to extinguish drug seeking and fear 
response behavior, which may challenge the assertion that Sxc is involved in 
gating how conditioned responses elicit future behavioral responses. Extinction, 
by definition, is a learning phenomenon whereby responding to CSs decreases 
when the outcome is omitted (Quirk & Mueller, 2008). Extinction learning has 
three phases: acquisition, consolidation, and retrieval. The acquisition phase is 
the initial learning phase whereby responses begin to decline due to a lack of 
reinforcement. This learning is then consolidated into a long-term memory which 
can be recalled during retrieval (e.g. reinstatement) to elicit a behavioral 
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response. As demonstrated by both the fear conditioning and cocaine self-
administration paradigms, there is no genotypic difference in the acquisition or 
consolidation of extinction memory. The lack of genotypic difference in 
acquisition of extinction may be explained by this phase being a new learning 
phenomenon similar to the initial conditioning phase. Specifically, we know that 
MSxc rats do no struggle with forming simple associations between CSs and 
outcomes and therefore we should expect them not to struggle with extinction 
acquisition. Additionally, CS responding during extinction training steadily 
declines over time in both genotypes which suggests that the new extinction 
memory is being remembered or consolidated. 
Intriguingly, the retrieval of extinction memories is impacted by loss of Sxc, 
but only under certain circumstances. In particular, retrieval of extinguished fear 
memory is not impacted by loss of Sxc whereas retrieval of cocaine seeking is, 
as evidenced by the increase in seeking in MSxc rats following a cocaine 
challenge.  This discrepancy in retrieval may exist due to the nature of the 
retrieval trigger, i.e. cocaine versus a light stimulus. Specifically, it is plausible 
that the cocaine rather than light stimulus has a greater impact on the already 
enhanced direct pathway neurons present in the MSxc rats and thus is more 
likely to facilitate the reinstatement of seeking. Further work is needed to explore 
the discrepancy in the genotypic differences in extinction memory retrieval but it 
highlights how discrete the loss of Sxc is, even within the same dimension of 
learning. Furthermore, these extinction training phenomena suggest that Sxc is 
involved in influencing how learned associations elicit changes in behavioral 
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response during tasks that require active attentional or working memory 
allocation. 
The major technical advancements of this work are the novel transgenic 
GFAP:Lck-eGFP rat to aid in studying the astrocyte transcriptome and the MSxc 
rat to study the importance of Sxc function in neurophysiology and behavior. 
Importantly, these animals allowed us and will hopefully allow others to advance 
our knowledge of the interplay between astrocytes, glutamate signaling, neural 
network activity and cognition. In support, FACS data collected from the 
GFAP:Lck-eGFP rat is consistent with experiments conducted in situ to 
investigate the expression of xCT in astrocytes (Ottestad-Hansen et al., 2018). 
An important note is that while some xCT expression is present in the GFP- 
sample, it is possible that we did not collect every astrocyte present in the 
sample. Notably, our sorting parameters were designed to exclude neurons from 
eGFP+ samples rather than isolate every astrocyte. As a result, the eGFP- 
sample also contained a very small number of astrocytes that were not 
completely disassociated from other cells.  
Additionally, the GFAP:Lck-eGFP rat revealed that GFAP expression can 
vary across brain regions. We observed the highest GFP expression in 
subcortical areas such as the thalamus as well as in the midbrain, brainstem, and 
cerebellum. The GFP signal in the neocortex, hippocampus, and striatum was 
comparatively lower. This is consistent with work done in human brain samples 
that demonstrate regional differences in GFAP expression, with subcortical 
regions expressing more GFAP than the neocortex (Torres-Platas, Nagy, Wakid, 
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Turecki, & Mechawar, 2016). While the reason underlying these differences 
remains unknown, the regional differences in GFAP expression appear to be 
phylogenetically conserved among rats and humans.  
The molecular and cellular changes resulting from loss of Sxc, while 
relatively minor, appear to be consistent with previous findings. It was surprising 
to not see a change in mGluR2/3 expression or its ability to regulate pre-synaptic 
release probability given previous work supporting group 2 mGluRs in relaying 
Sxc dependent signals (Baker et al., 2002). However, the xCT null mutant mice 
did not display changes in pre-synaptic plasticity, consistent with our findings (Y. 
Li et al., 2012). Additionally, pT840/GluA1 density was increased in hippocampal 
synapses of xCT knockout mice which corresponded to an increase in 
spontaneous and evoked EPSCs (Williams & Featherstone, 2014). We found a 
similar increase in the NAcc of our MSxc rats and established that this  
phenomenon may occur in a pathway specific manner given that enhanced 
mEPSCs were found only in the direct pathway.  
The mechanism underlying how only the direct pathway is influenced by 
loss of Sxc or how Sxc can regulate GluA1 phosphorylation remains unresolved. 
We speculate that there could be differences in the proximity of Sxc to NAcc 
efferents or that the neuronal receptor responsible for receiving Sxc derived 
glutamate that is regulating GluA1 is differentially expressed or no longer being 





dephosphorylation of T840/GluA1 (Delgado et al., 2007). Given the lateral 
diffusion capabilities of NMDARs (Groc et al., 2004), they may be in a position to 
receive non-synaptic glutamate signals from astrocytes. Indeed, NMDAR 
activation via glutamate release from astrocytes produces slow inward post 
synaptic currents (SICs). What makes SICs unique are their slow kinetics and 
dependency on the proximity of an astrocyte (Fellin et al., 2004; Kovacs & Pal, 
2017). Our data suggest that Sxc may signal through NMDARs to influence 
GluA1, and this will be directly tested in subsequent experiments. 
Figure 2-15: Model of the tripartite synapse in the NAcc. Our findings demonstrate a link 
between astrocyte to neuron signaling via Sxc being a critical component of neural network 
regulation and ultimately executive control over behavior. Previous work suggests Sxc 
communicates through pre-synaptic mGluRs to gate synaptic release while this work 
demonstrates Sxc can gate AMPA receptor signaling, likely through activation of 
extrasynaptic NMDARs. This will be explored later. 
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Sxc and EAATs such as GLT-1 have been suggested to be strongly co-
regulated (Knackstedt, Melendez, & Kalivas, 2010). While it was surprising that 
we saw no change in GLT-1 expression, we chose to investigate changes in D-
aspartate uptake, which is a more general measure of EAAT function. Not 
surprisingly we saw a reduction in D-aspartate uptake in MSxc tissue and cells, 
which is consistent with the co-regulation hypothesis of Sxc and EAATs. A 
limitation of this study is that only a single concentration of D-aspartate was 
used. Future experiments will be aimed at investigating changes in transport 
kinetics which may help elucidate the nature of this apparent reduction in 
function.  
Understanding brain function is one of the greatest challenges in modern 
science; it also has among the highest potential to reduce the burden of human 
disease. However, a paradigm shift in neuroscience may be needed for dramatic 
advances in understanding the human brain. Given our findings, perhaps the 
description of astrocytes as mere metabolic support cells is emerging as an 
example of an overly simplistic and possibly inaccurate perspective that is 
limiting the progress of modern neuroscience research. Incorporating advances 
and approaches from artificial intelligence, evolution, and other disciplines have 
the potential to transform efforts to understand the healthy and diseased brain to 
uncover novel therapeutic strategies.  Our data are consistent with the possible 
organization of glutamate signaling whereas evolutionarily newer glutamate-
release mechanisms expressed by astrocytes, e.g. Sxc, have a restricted, 
specialized set of functions in regulating neural circuits and cognition. Hence, 
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further work into evolutionarily newer forms of intercellular signaling may enable 
the selective manipulation of discrete domains of brain activity, such as cognition 
















































 The previous chapter establishes Sxc as a critical component in cognitive 
processing. Sxc appears to be necessary for gating the influence that 
environmental stimuli and their learned associations have on eliciting an 
appropriate behavioral response. Considering this, the next question to address 
is how Sxc is involved in this process. Specifically, there is a need to determine 
what molecular factors are influencing Sxc function and the mechanisms 
underlying Sxc regulation of neural circuits in a manner relevant for cognitive 
control.  
When we consider the NAcc tripartite model, incoming stimulus 
information is largely conveyed by the afferent neurons which transmit their 
information to the direct pathway to drive a behavioral output.  An unresolved 
question is how and when astrocytes are recruited for the regulation of neural 
circuits. Theoretically, if the complexity of the incoming information is high, neural 
networks may recruit astrocytes to aid in processing of information to increase 
efficiency and expedite an appropriate response. If this is true, then perhaps 
neurons release a factor signaling to astrocytes that they are needed to assist 








The previous chapter established that xCT acquired novel kinase 
regulatory sites during vertebrate evolution which may have allowed neural 
factors to signal through astrocytes and regulate Sxc function which in turn, 
allowed Sxc to impact encoding of environmental information. There are three 
proposed regulatory sites on the human sequence of xCT that are conserved in 
rats: S26, S185, S481. These serine residues match consensus sequences for 
CaMKII/MSK1 and GSK-3 (Figure 3-1). Intriguingly, the degree of conservation 
among these sequences is different, with the GSK-3β site having a 92% 
conservation rate and the two MSK1 sites having rates of 57% and 39% (S26 
and S481 respectively). Furthermore, the emergence of S26 occurs in some 
reptiles and most birds, but expression falls in mammals but becomes stoic in 
primates. Likewise, S481 emerges first in mammals and is present in all 
primates, suggesting that these regulatory sequences were recently acquired 
and may be downstream targets of a variety of intracellular signaling cascades 
triggered by multiple neural factors. This leads to the questions; which neural 
factors regulate Sxc and what are the functional changes resulting from these 
biophysical adaptations? 
Figure 3-1: Conservation 




were deemed conserved 
so long as the base 
consensus sequence was 
retained; R-X-X-S and S-X-
X-X-S for CaMKII/MSK1 
and GSK-3β respectively. 
481 26 185 
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In order to investigate the contribution of neural factors to the function of 
Sxc, we chose to explore three possible sources of influence: the post-synaptic 
neuron, pre-synaptic neuron, and hormones and select a molecular factor that 
might target one of these sites. First, the post-synaptic neuron could be 
contributing to the regulation of Sxc. Recent studies support a role of 
endocannabinoid mobilization in striatal efferents which act on the cannabinoid-1 
receptor (CB1R) in adjacent astrocytes which drives glutamate release at homo-
typic, hetero-synaptic circuits. This glutamate activates neuronal mGluRs and 
consequently enhances synaptic glutamate signaling and thus output power 
(Martin et al., 2015). Importantly, the mechanism that releases glutamate from 
astrocytes in this study was not investigated, which questions whether Sxc is 
involved. Furthermore, CB1R activation has been shown to regulate GSK-3β 
which targets S185 of xCT (Ozaita, Puighermanal, & Maldonado, 2007). 
 Regarding the pre-synaptic terminal, the neuropeptide PACAP1-38 
(shorthand PACAP) is co-released with glutamate and can influence the 
expression and function of glutamate transporters in astrocytes such as Sxc 
(Kong et al., 2016; Resch et al., 2014) and GLT-1 (Figiel & Engele, 2000) in 
addition to neuronal NMDARs and AMPARs (Toda & Huganir, 2015; Yaka, He, 
Phamluong, & Ron, 2003). However, the rate in which PACAP influences Sxc 
and GLT-1 is slow, as it takes days of application in vitro to see changes in 
expression and function. Rapid effects of PACAP on Sxc function remain to be 
studied and these findings would have important implications for the potential to 
rapidly influence neural networks. Furthermore, PACAP has been shown to 
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influence MSK1, which targets S26 and S481 of xCT (Butcher, Lee, Cheng, & 
Obrietan, 2005). 
Lastly, hormones could potentially be influencing Sxc function. A recent 
study has suggested that Sxc is a resilience factor for stress by observing that a 
reduction in the expression of xCT was present in the ventral hippocampus of 
mice exposed to chronic restraint stress for 21 days. Remarkably, when n-
acetylcysteine was orally administered during the last 3 days of stress exposure, 
xCT expression was restored and social interaction behavior improved (Nasca et 
al., 2017). This finding calls into question whether stress related hormones such 
as corticosterone are influencing the expression or function of Sxc. Furthermore, 
glucocorticoids have been shown to activate MSK1 and drive its translocation 
from the nucleus to the cytosol which would put it in position to regulate S26 or 
S481 of xCT. 
Conducting a series of in vitro experiments using cultured astrocytes, we 
investigated the ability for endocannabinoid, PACAP, and corticosterone 
signaling to influence the function of Sxc through cystine uptake or cystine-
evoked glutamate release. These findings will help illuminate how neural and 
hormonal factors regulate astrocytes through modulating Sxc function and in turn 
regulate neural circuits to encode incoming stimulus information. 
MATERIALS AND METHODS 
Cell Culture: Astrocyte cultures were generated from postnatal day-3 rat pups. 
The striatum was dissected and dissociated using 0.25% trypsin EDTA (Gibco) 
and cultured in 75 cm2 flasks in a humidified incubator at 37°C under 95% O2 5% 
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CO2 in Eagles minimum essential medium (Gibco) supplemented with 5% fetal 
bovine serum/5% horse serum (Atlanta Biologicals), Glutamax (Gibco), and 
antibiotics/antimycotics (Gibco). To remove debris and non-astrocytic glia, flasks 
were agitated, and the resulting mono-cell layer was resuspended with 0.25% 
trypsin EDTA. Cells were counted by hand via a cytometer and seeded in 24-well 
plates coated with poly-D-lysine and laminin at a density of 200,000 cells per 
well.  
Glutamate release assay: Striatal astrocytes (DIV14) were incubated for 30 
minutes at 37oC in Na+-free buffer containing the following: 116 mM choline 
chloride, 13.4 mM MgSO4, 1.68 mM KH2PO4, 2.34 mM CaCl2, 5.49 mM 
dextrose, 11.9 mM HEPES, 0.2% choline bicarbonate, titrated to pH: 7.4 with 
CeOH. This buffer was used to prevent Na+-dependent uptake of glutamate. L-
cystine (12.5 or 200 M) were applied to drive cystine-glutamate exchange by 
Sxc. These concentrations were chosen because they approximate the required 
cystine for Km and Vmax of xCT transport. Corticosterone-HBC and PACAP 
treatments were applied for 30 minutes at which point media samples (100 l) 
were collected for subsequent glutamate analysis using HPLC. Cells were then 
dissolved in 0.5% SDS and total protein for each well was quantified using the 
BCA method. 
Glutamate HPLC: The concentration of glutamate was quantified by comparing 
peak areas from samples and external standards using HPLC coupled to 
fluorescence detection. A 10 l sample underwent pre-column derivatization with 
orthophthaladldehdye (OPA) in the presence of 2-mercaptoethanol using a 
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Shimadzu LC10AD VP autosampler. Chromatographic separation was achieved 
using a Kinetex XB C-18 (50 x 4.6 mm, 2.6 m; Phenomenex) and a mobile 
phase consisting of 100 mM Na2HPO4, 0.1 mM ethylenediaminetetraacetic acid 
(EDTA), 10% acetonitrile at a pH of 6.04. Glutamate was detected using a 
Shimadzu 10RF-AXL fluorescence detector with an excitation and emission 
wavelength of 320 and 400 nm, respectively. Glutamate content for each sample 
was normalized to total protein in the respective well and depicted as a net 
change from baseline. The data was fit using the Michaelis-Menten equation to 
determine Km and Vmax. 
14C-L-Cystine Uptake Assay: Cultures were rinsed with 1x HBSS media prior to 
application of vehicle [1x HBSS, 1% FBS, 0.1% dimethylsulfoxide (DMSO), 
200nM 14C-L-Cystine] or WIN55 [1x HBSS, 1% FBS,1µM WIN55,212, 200nM 
14C-Cystine] treatment solutions. Plates were incubated at 37oC for 20 minutes 
followed by three rinses with 1x HBSS. Cells were lysed with 300µL of 0.5% 
sodium dodecyl sulfate (SDS) per well. A 200µL aliquot was taken for scintillation 
count and a 25µL aliquot was taken for BCA assay. 
Data analysis: All experiments were analyzed using a two-way ANOVA with a 
Tukey post-hoc test. Data are presented as mean ± SEM. 
RESULTS 
An in vitro radiolabeled cystine (14C-L-cystine) uptake assay was utilized 
to ascertain the sufficiency for a CB1R agonist (WIN55,212) to rapidly enhance 
Sxc-dependent cystine uptake (Figure 3-2; n=11-12/genotype). A two-way 





(F1,42= 1073.739, p<0.05), with a significant interaction between these variables 
(F1,42= 7.475, p<0.05). Post-hoc tests revealed a significant increase in 14C-L-
cystine uptake in WIN55,212 treated WT but not MSxc cells (Tukey, p<0.05). 
These data demonstrate that CB1R agonism rapidly enhances Sxc dependent 
cystine uptake within 20 minutes and loss of Sxc greatly reduces cystine uptake. 
Next, an in vitro cystine-evoked glutamate release assay was conducted 
to determine the effect of PACAP application on extracellular glutamate in WT 
and MSxc cells (Figure 3-3; n=6-12/genotype). One cystine concentration were 
used in this experiment, 12.5 µM, which approximates the Km of Sxc mediated 
transport.  A two-way ANOVA revealed a main effect of genotype (F1,40= 
275.645, p<0.05) and treatment (F3,40= 4.492, p<0.05) with a significant  
Figure 3-2: CB1R 
agonism enhances Sxc 
dependent cystine 
uptake. Data depicts 
mean ± SEM radioactivity 
of WT and MSxc cell 
samples treated for 20 
minutes with radiolabeled 
L-cystine with or without 
the CB1R agonist 
WIN55,212.  L-cystine 
was applied at a 
concentration of 200 nM. 
Two-way ANOVA, Tukey 
post-hoc test; # effect of 
genotype within 







interaction between these variables (F3,40= 4.003, p<0.05). There was a large 
reduction in extracellular glutamate in MSxc cells within each PACAP treatment 
group (Tukey, p<0.05). Within WT cells, PACAP dose-dependently increased 
extracellular glutamate (0 nM vs 10 and 100 nM; Tukey, p<0.05). This  
phenomenon did not occur in MSxc cells (Tukey, p<0.05). These data 
demonstrate that PACAP can rapidly increase extracellular glutamate in an Sxc- 
dependent manner and that loss of Sxc greatly reduces extracellular glutamate. 
Lastly, an in vitro cystine-evoked glutamate release assay was conducted to 
determine the effect of corticosterone application on extracellular glutamate in 
WT cells (Figure 3-4; n=3-4/treatment). Two cystine concentrations were used in 
this experiment: 12.5 and 200 µM, which estimate the Km and Vmax of Sxc 
mediated transport, respectively. A two-way ANOVA revealed an interaction 
between treatment and cystine (F2,16= 3.762, p<0.05). There was a dose 
dependent increase in extracellular glutamate resulting from corticosterone  
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treatment (0 vs 100 nM) within the 12.5 µM cystine treatment group (Tukey, 
p<0.05). This phenomenon did not occur in the 200 µM cystine treatment group 
(Tukey, p>0.05). These data demonstrate that corticosterone significantly  
enhances cystine-evoked glutamate release when rates of uptake are near the 
Km but not Vmax of transport.    
DISCUSSION 
 These data establish three potential sources of influence for Sxc function: 
the pre-synaptic neuron, post-synaptic neuron, and hormonal milieu. We chose 
to investigate the endocannabinoid, PACAP, and corticosterone signaling due to 
the likely possibility that they are influencing one or more of the putative 
regulatory sites on xCT: S26 and S481 which are regulated by MSK1 and S185 


































astrocytes in a 
cystine-dependent 
manner. Data depicts 
mean ± SEM 
extracellular 
glutamate evoked by 










evidence that PACAP, corticosterone and CB1R agonism can rapidly influence 
Sxc function. Given the predicted kinase regulatory sites on xCT via MSK1 and 
GSK3, there is a clear need to investigate how these factors might be influencing 
these kinases. Additionally, the extent to which these factors influence behavior 
through Sxc remain to be studied, but given the findings in the MSxc rat, it is 
possible that these factors can modify how astrocytes regulate neural networks 
and behavior.  
 The impact of corticosterone on Sxc function appears to be specific to the 
efficiency of transport or Km given that glutamate release was only impacted at 
12.5 µM L-cystine. Effectively, this means that Sxc can expel more glutamate at 
lower cystine concentrations. Unfortunately, it is not currently understood how 
Sxc does this, but it may be through a biophysical adaptation caused by 
phosphorylation of the xCT subunit which increases the transport probability of 
cystine and glutamate. Furthermore, we did not control for effects independent of 
Sxc, as a negative control such as sulfasalazine treated or MSxc cells were not 
treated with corticosterone. Future experiments will be aimed at understanding 
whether the effects seen here are Sxc dependent and if so, how corticosterone 
may change the phosphorylation of xCT. Given the link between glucocorticoid 
signaling and activation of MSK1 (Beck et al., 2013), we hypothesize that S26 or 
S481 are likely impacted by corticosterone. 
The impact of corticosterone on Sxc function may have implications for 
cognitive control as stress can influence performance in behavioral flexibility 
tasks (Hurtubise & Howland, 2017). Intriguingly, the intensity of the specific 
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stress paradigm can differentially impact performance in set shifting or reversal 
learning. Mild stressors such as a brief 30-minute restraint or being placed on an 
elevated platform prior to testing would improve reversal learning suggesting that 
stress in this context is providing an adaptive advantage. Conversely, repeated 
exposure to stressors for a week or more broadly impaired set shifting and 
reversal learning which suggests that stress over prolonged periods of time 
produces a maladaptive behavioral phenotype. Because Sxc has been linked to 
stress resiliency (Nasca et al., 2017) it is feasible that stress hormones such as 
corticosterone could be affecting Sxc function and consequently changing the 
behavioral response to acute and chronic stressful stimuli. Future work should be 
aimed at investigating this link. 
 Given our experimental design, we cannot determine the effect of CB1R 
agonism on Sxc kinetics. At best, due to the use of a low concentration of L-
cystine (1 µM), we can speculate that the increase in L-cystine uptake seen with 
CB1R agonist treatment is indicative of a reduction in Km of Sxc transport. Much 
like with the effect of corticosterone, how CB1R agonism increases the efficiency 
of Sxc transport is unknown but likely involves a phosphorylation event. 
Importantly, this finding illuminates Sxc as one of the mechanisms that is 
involved in CB1R-dependent glutamate release from astrocytes. The finding that 
CB1R signaling in astrocytes leads to pathway specific regulation of neural 
circuits via glutamate release mirrors our findings in the first chapter 
demonstrating that loss of Sxc induces a pathway specific enhancement of 
excitatory output from the NAcc (Martin et al., 2015). While this paper did not 
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investigate the glutamate release mechanism downstream of CB1R, we can 
speculate that one of the targets may be Sxc. Furthermore, CB1R activation has 
been shown to regulate GSK-3β which targets S185 of xCT (Ozaita et al., 2007). 
Given this, future experiments aimed at understanding the link between Sxc and 
the endocannabinoid system are warranted and may reveal how 
endocannabinoids influence astrocytes to regulate behavioral control. 
Like corticosterone, the endocannabinoid system can produce effects on 
performance in behavioral flexibility tasks, which are suggestive of its link to Sxc 
function. For example, when the CB1R antagonist AM251 is administered at low 
doses prior to a spatial to visual cue or visual cue to spatial shift in response 
strategy, the number of perseverative errors committed were reduced. 
Intriguingly, higher doses did not produce this effect. Furthermore, when the 
CB1R agonist HU-210 is administered, there are dose-dependent effects on 
perseverative errors with low doses reducing and higher doses increasing these 
errors. Intriguingly, the low dose of HU-210 increased the number of regressive 
errors made when shifting towards a spatial cue which suggests latent inability to 
maintain the new behavioral strategy after sufficient successful trials. This may 
be due to the difficulty in shifting away from the visual cue which has both visual 
and tactile qualities and makes it a more salient cue relative to spatial cues (Hill, 
Froese, Morrish, Sun, & Floresco, 2006). Thus, the potential for stimuli and the 
learned associations about them to influence behavior is in part determined by 
endocannabinoid signaling. An important follow up experiment will involve 
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manipulating the endocannabinoid system in WT and MSxc rats to determine the 
necessity of Sxc in these behavioral changes. 
Lastly, the finding that PACAP dose-dependently and rapidly enhances 
Sxc-dependent cystine-evoked glutamate release from astrocytes mirrors 
previous findings that long-term incubation increases Sxc expression and 
function (Kong et al., 2016; Resch et al., 2014). The rapid nature of this 
enhancement is critical, since for PACAP to rapidly influence behavior, the 
signaling mechanism needs to be able to quickly modulate Sxc function. Again, 
we speculate that this rapid regulation likely comes in the form of a 
phosphorylation event, possibly at one of the serine residues. Notably, there is a 
link between PACAP signaling and regulation of MSK1 which targets S26 and 
S481 of xCT (Butcher et al., 2005). Future experiments will investigate the 
intercellular signaling pathway that links PACAP receptors and Sxc.   
 The ability for PACAP to influence cognitive control remains 
understudied. What is currently known about the influence of PACAP on 
instrumental behaviors comes from a comprehensive behavioral battery 
conducted on PACAP KO mice (Hattori et al., 2012). In this study there were 
remarkable increases in locomotor activity and social interaction but no 
discernable differences in working memory tasks such as forced alternation and 
left-right discrimination. However, there was an increase in the number of 
revisiting trials during a radial arm maze task only when the delay period in 
between trials was high. Unfortunately, the authors did note that some PACAP 
KO mice died during this test due to food restriction which may have influenced 
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the outcome. Because of the limitations of the species used, a more direct 
investigation of the ability for PACAP signaling to regulate cognitive processing in 
rat is required.  
Collectively, these data establish three molecular factors are influencing 
Sxc function. The next question that needs to be resolved is what are the 
mechanisms underlying how neural factors signal through astrocytes and 




















THE NEUROPEPTDE PACAP COORDINATES NEURON-ASTROCYTE 
GLUTAMATE SIGNALING IN THE NUCLEUS ACCUMBENS CORE TO 




 The previous chapters have established the complexity of intercellular 
communication in the brain and how the emergence of astrocytes and their ability 
to release glutamate may have been a critical component involved in mammalian 
cognition. However, our findings up until this point have been lacking insight into 
how glutamate signals from astrocytes are encoded by neurons to modify 
behavior. While the previous chapter suggests that neural and hormonal factors 
have the capability of influencing Sxc function in vitro, there is a disconnect 
between the production of this signal and the signal transduction mechanism that 
alters neural network activity in vivo. The importance of neuron-astrocyte-neuron 
communication may be to encode when astrocytes are required for processing of 
complex information to elicit an appropriate behavioral response. Effectively, this 
grants neurons the ability to influence astrocyte function and consequently 
regulate adjacent synapses to either enhance or inhibit excitatory output and 
behavioral action. Thus, the goal of the following experiments was to investigate 
how an endogenous neuronal factor regulates Sxc within astrocytes and 
consequently alters neuronal activity and contributes to cognitive processing.  
PACAP1-38, (shorthand PACAP) is a particularly interesting factor because 
of its ability to broadly regulate the glutamate system. Specifically, PACAP has 
been shown to regulate the expression and function of Sxc and GLT-1 as well as 
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AMPARs and NMDARs (Figiel & Engele, 2000; Kong et al., 2016; Resch et al., 
2014; Toda & Huganir, 2015; Yaka et al., 2003) . Additionally, PACAP levels 
decrease in the aging brain which correlates with a reduction in cognitive function 
(Han et al., 2017). However, there are important questions about a potential link 
between these two outcomes; is it possible for changes in astrocytic glutamate 
transport to alter post-translational modification of neuronal glutamate receptors 
and consequently influence excitatory output and cognitive control? 
In support of this link, our data in conjunction with others, have established 
signaling mechanisms involving Sxc and their impact on neuronal signaling and 
behavior. Sxc can signal through extrasynaptic glutamate receptors within the 
pre- and post-synaptic domain. In the pre-synaptic domain, Sxc signals through 
group 2 mGluRs which are Gαi coupled and when activated, attenuate the 
opening of voltage-gated Ca2+ channels consequently preventing vesicular 
release of glutamate or dopamine (Baker et al., 2002). Post-synaptically, Sxc 
influences AMPAR function through diminishing the phosphorylation of T840 of 
GluA1 which is thought to either reduce ion conductance or reduce synaptic 
localization of AMPAR (Williams & Featherstone, 2014). Although, the 
mechanism linking dephosphorylation of AMPAR with Sxc activity has not been 
demonstrated, T840 is decreased by NMDAR activation (Delgado et al., 2007). 
Given that NMDARs can receive extrasynaptic glutamate signals, it is possible 
that Sxc may be communicating through these receptors to regulate AMPARs. 
Furthermore, PACAP signaling in neurons dephosphorylates T840 and this 
phenomenon is dependent on NMDAR activation (Toda & Huganir, 2015). Thus, 
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we hypothesize that PACAP may have independent signaling mechanisms in 
neurons and astrocytes that are linked by glutamate release via Sxc to regulate 
GluA1. 
Considering the link between PACAP, Sxc, NMDARs, and AMPARs, how 
can these components interact in a way to alter behavior? Importantly, Sxc 
expression declines following withdrawal from cocaine (Baker, McFarland, Lake, 
Shen, Tang, et al., 2003), nicotine (Knackstedt et al., 2009), and opioid (Alshehri, 
Hakami, Althobaiti, & Sari, 2018) intake which produces a drop in extrasynaptic 
glutamate. This could cause a disinhibition of GluA1 T840 dephosphorylation 
which in turn could enhance neural outputs in a pathological manner. Consistent 
with this, chapter 2 illustrated how loss of Sxc function caused a pathway specific 
enhancement of the direct pathway from the NAcc which has been linked to drug 
seeking behavior (Lobo et al., 2010). Importantly, the mechanism underlying this 
reduction in expression is unknown. One possibility is that a neural factor could 
be regulating Sxc expression and upon cessation of drug consumption, the factor 
becomes impaired which produces the effect on Sxc.  It is possible that PACAP 
signaling may become dysregulated because of substance abuse, but no 
evidence exists at this time. However, given the importance of glutamate 
signaling in the NAcc for the reinstatement of drug seeking and the sufficiency of 
Sxc to attenuate it, we determined that investigating PACAP signaling in this 
brain region would be appropriate.  
99 
 
Thus, we tested the hypothesis that PACAP enhances Sxc function and 
coordinates the reception of its glutamate signal in neurons to regulate neural 
networks and consequently drug seeking behavior in the NAcc. 
MATERIALS AND METHODS 
Chemicals: Unless noted, common chemicals and reagents were obtained from 
Sigma Aldrich. 
Animal care and usage: Male Sprague Dawley rats were used for these 
experiments. Housing conditions and experimental protocols were approved by 
Institutional Animal Care and Use Committees at the Medical College of 
Wisconsin or Marquette University, and were carried out according to the US 
National Institutes of Health guidelines. 
Creation of GFAP:Lck-eGFP transgenic rats: The Sleeping Beauty (SB) 
transposon transgenesis method(Geurts et al., 2010) was used to produce 
transgenic rats on the Sprague Dawley (Crl:SD) background. Briefly, a GFAP 
promoter-driven fusion between the plasma membrane targeting myristolation 
domain of the mouse LCK protein fused to eGFP (Benediktsson et al., 2005) was 
synthesized (GeneArt) and cloned into a SB transposon vector. The transposon 
plasmid was co-injected with a source of SB100X transposase mRNA into the 
pronucleus of fertilized Crl:SD embryos. A breeding colony was established 
harboring a single copy of the transgene inserted on rat chromosome 13 
enabling robust eGFP expression. To confirm expression in situ, a rat was deeply 
anesthetized and transcardially perfused with 4% paraformaldehyde. The brain 
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was extracted and sliced at 100 µm and GFP signal was visualized using 
standard fluorescence microscopy. 
Creation of MSxc rats: Zinc-finger nucleases (ZFNs) were designed targeting 
the second exon sequence 
(TGCTAGCTTTTGTTCgagtcTGGGTGGAACTGCTG) to produce small deletions 
of a limited number of base pairs in the Slc7a11 gene, where capital letters 
represent binding sites for the individual ZFN monomers, on opposite strands. 
ZFNs were injected into the pronucleus of Sprague Dawley (Crl:SD) rat embryos 
by pronuclear microinjection of in vitro-transcribed encoding messenger RNAs 
and the resulting offspring were screened for mutations using a Cel-1 assay and 
validated by Sanger sequencing as previously described (Geurts et al., 2010) 
and resulting in single-step, whole-animal disruption of Slc7a11 (MSxc rats). 
Deletion of 39 consecutive base pairs 
(GAGGTCTTTGGTCCCTTGCTAGCTTTTGTTCGAGTCTGG) of exon 2 was 
confirmed by Sanger sequencing.  
Tissue Dissociation for FACS: NAcc tissue was dissected from male GFAP-
lck-eGFP or WT Sprague Dawley rats and placed into ice-cold Hanks´ Balanced 
Salt Solution without Ca2+ or Mg2+. Tissue was mechanically and enzymatically 
dissociated to obtain single-cell suspension using Neural Tissue Dissociation Kit 
- P (Miltenyi Biotec). 1% BSA, 1mM EDTA and 12.5 U/ml DNase I were added to 
reduce cell clustering. Cells were incubated with 3 µM Calcein Violet 450 AM 
Viability Dye (eBioscience) on ice for 10 minutes to stain live cells. An aliquot 
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from each cell suspension was used to determine relative gene expression in 
sorted and unsorted (total) cells. 
Flow Cytometry: FACS analyses were performed using FACSDiva software 
6.1.3 (BD Biosciences). Control samples (tissue obtained from rats lacking the 
GFAP:Lck-eGFP transgene) were analyzed first to identify the range of 
endogenous or background fluorescence intensity. In addition, the gating 
parameters of the flow cytometer were set to isolate live, eGFP+ cells from 
cellular debris, and cell doublets. Note, the eGFP- samples contain all tissue 
excluded from the eGFP+ sample and would be expected to include eGFP- cells, 
cell doublets, fragmented cells, and potentially eGFP+ cells that were not 
excluded due to the use of strict gating parameters or incomplete cellular 
disassociation. 
RNA amplification and Reverse Transcription: FACS samples were 
centrifuged (170xg, 5 min) and the supernatant was carefully extracted. Cells 
were lysed using the cell lysis solution provided within the cDNA Synthesis from 
Cell Lysates kit (Lucigen). This kit was used as per the manufacturer’s 
instructions to amplify the RNA and reverse transcribe to cDNA for use in PCR or 
qPCR. Briefly, a T7 RNA polymerase promoter was annealed to the RNA and 
was reverse transcribed using MMLV reverse transcriptase. In vitro transcription 
was performed, and the RNA product was treated with DNAse and purified using 
the RNA Clean and Concentrator kit (Zymo). The RNA was then incubated at 
70oC and rapidly cooled to 4oC. A final reverse transcription step yielded cDNA 
for use in downstream applications. 
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RT-PCR: PCR was conducted using GoTaq DNA polymerase (Promega). Primer 
sequences were as follows: Slc7a11 (xCT) forward- 5’ AGG GCA TAC TCC AGA 
ACA CG 3’; Slc7a11 reverse- 5’ TTT AGT CCC ATC AGG TCG TTG 3’; GAPDH 
forward- 5’ CTC CCA TTC TTC CAC CTT TGA 3’; GAPDH reverse- 5’ ATG TAG 
GCC ATG AGG TCC AC 3’; GFAP forward - 5’ GCA GGT GAG GAA GAA ATG 
GA 3’; GFAP reverse - 5’ TAC GAT GTC CTG GGA AAA GG 3’; RbFox3 forward 
- 5’ ATC ATA CCA TCG GCC CCA CA 3’; RbFox3 reverse - 5’ GTG AAG CGG 
CTG TAC CCT CC 3’; ADCYAP1R1 forward – 5’ ATT CTT TCT CCC TCC CCT 
GA 3’; ADCYAP1R1 reverse – 5’ TGG AGT ACC AAG GGC TGA AC 3’; VIPR1 
forward – 5’ AGG GAA AGG ACA GAG CAA CC 3’; VIPR1 reverse - 5’ GGC 
CTC TAC CAG GAC TTT CC 3’; VIPR2 forward – 5’ GTG CTA CAA GCC CTG 
GTG TC 3’; VIPR2 reverse – 5’ GGT CAC GCC TAG TGG TTG AT 3’; PACAP 
forward - 5′ AAC CCG CTG CAA GAC TTC TA 3′; PACAP reverse- 5′ CTT TGC 
GGT AGG CTT CGT TA 3′. 
Western Blotting: NAcc tissue samples obtained from adult WT and MSxc rats 
(i.e., > 90 days old) underwent mechanical homogenization in a sucrose-based 
buffer (300 mM sucrose, 10 mM Tris-HCl, pH 7.4) containing protease and 
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentration for each 
whole cell lysate sample was determined via the bicinchoninic acid assay (BCA). 
Protein (10 g) was resolved in a 7.5% polyacrylamide gel and wet transferred to 
Immobilon PVDF membranes (EMD Millipore). Membranes were immersed for 
one hour in blocking buffer (LiCOR) prior to overnight application at +4°C with a 
primary antibody: rabbit anti-pT840 GluA1 (Abcam, 1:3,333), mouse anti-GluA1 
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(EMD Millipore, 1:1000), rabbit anti-S897 GluN1 (Abcam, 1:1000), and mouse 
anti GluN1 (Abcam, 1:1000). Secondary antibodies (LiCOR) goat anti-rabbit IR 
680 DYE (1:15000) donkey anti-mouse IR 800 DYE (1:20,000) were applied for 1 
hour at room temperature prior to imaging (Odyssey Fc Imaging System, 
LiCOR). Band intensity was quantified using LiCOR Image Studio software and 
the resulting data are presented as the target protein band intensity divided by 
the reference protein band intensity. 
Cell Culture: Astrocyte cultures were generated from postnatal day 3 rat pups. 
Briefly, the striatum was dissected and dissociated using 0.25% trypsin EDTA 
(Gibco) and cultured in poly-D-lysine and laminin treated 75cm2 flasks in a 
humidified incubator at 37°C under 95% O2 5% CO2 in Eagles minimum essential 
medium (Gibco) supplemented with 5% fetal bovine serum/5% horse serum 
(Atlanta Biologicals), Glutamax (Gibco), and antibiotics/antimycotics (Gibco). To 
remove contaminating glia and dead cells, the flasks were agitated, and the 
resulting mono-cell layer was resuspended with 0.25% trypsin EDTA. Cells were 
counted by hand via a cytometer and seeded in 24-well plates coated with poly-
D-lysine and laminin at a density of 200,000 cells per well.  
D-Aspartate Uptake Assay: Striatal astrocytes (DIV14) were incubated for 30 
minutes at 37oC in HEPES buffered Hanks Balanced Salt Solution. A range of D-
aspartate concentrations (0, 12.5, 50, 200, 800 µM) were applied to drive uptake 
Vehicle saline or PACAP (100 pmol) were concurrently applied for 30 minutes. A 
100 μL media sample was taken for HPLC analysis. Clearance was quantified by 
subtracting the concentration of D-aspartate left in the media from the known 
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input concentration. Cells were then dissolved in 0.5% SDS and total protein for 
each well was quantified using the BCA method. 
Glutamate/Aspartate HPLC: Glutamate and aspartate content was measured 
using fluorescence detection on an isocratic HPLC system (Shimadzu). A 10 μL 
sample underwent pre-column derivatization with orthophthaladldehdye (OPA) in 
the presence of 2-mercaptoethanol. Samples were resolved with a Kinetex XB C-
18 (50x4.6mm, 2.6μm; Phenomenex, Torrence, CA) and 100mM Na2HPO4, 
0.1mM Ethylenediaminetetraacetic acid (EDTA), 10% Acetonitrile, pH: 6.04 
mobile phase. Peaks areas were quantitated in Shimadzu VP client software 
compared to known standards. Glutamate and aspartate content for each sample 
was normalized to total protein in the respective well.  
Cocaine Self-Administration: Rats were trained to self-administer cocaine (0.5 
mg/kg/inf, IV; 6 hr/day) or saline under a fixed ratio one schedule of 
reinforcement for 12 daily sessions.  Rats then underwent a two-week abstinence 
period during which time they underwent stereotaxic surgery for cannula 
implantation targeting the NAcc (6o, +1.2 mm anterior-posterior, +2.2 mm medial-
lateral, -4.8 mm dorsal-ventral; injectors projected 2 mm past the end of the 
cannula). One week following recover, rats underwent extinction training 
sessions, which were identical to the self-administration sessions except lever 
presses resulted in saline infusions.  Once rats met the extinction criterion of 
fewer than 15 presses/day, reinstatement testing was conducted.  Reinstatement 
testing involved pretreatment with a high dose of cocaine (10 mg/kg, IP) in 





pmol/side), RO-25-6981 (2 µg/side), SKF 81297 (0.125μl/min, 0.5μl total volume, 
3 µg/side) ten minutes prior to testing and recording lever pressing for 2 hours.    
Rhodamine Tracer injection: Wild type and Sxc rats were anesthetized with 
ketamine/xylazine and underwent stereotaxic surgery. Guide cannula (Plastics 
One) were implanted into the brain targeting the substantia nigra (0°, -5.0mm 
anterior-posterior, +2.1mm medial-lateral, -6.1mm dorsal-ventral) or ventral 
pallidum (0°, -0.6mm anterior-posterior, +2.8mm medial-lateral, -6.3mm dorsal-
ventral). Micro injectors (Plastics One) were inserted into the cannula projecting 
+2.0mm to the target structure. 300 nL of rhodamine fluorescent latex 
microspheres (Lumafluor) were injected into the target region. Animals recovered 
for 2 weeks prior to use in experiments.    
Electrophysiology: Whole-cell voltage-clamp recordings were made from 
medium spiny neurons (MSNs) in the core of the nucleus accumbens (NAc). 
MSNs retrogradely labeled with red beads that originated from either the SN or 
VP were selected for recording. NMDAR currents were induced by pressure 
ejection of NMDA and recorded at holding potential of -80 mV, -60 mV, -40 mV, -
20 mV, 0 mV, 20 mV and 40 mV in the present of AMPAR antagonist CNQX (20 





µM) and GABAA receptor blocker picrotoxin (100 µM). NMDA (25 µM) was 
pressure-ejected (5 psi, 300 ms) with a glass pipette (~1 µm tip opening). The I-V 
curve of NMDAR currents showed strong inward rectification due to Mg2+ (1.3 
mM) blockade at negative holding potentials. 
RESULTS 
To investigate the role of PACAP signaling in the reinstatement of drug 
seeking, we employed a long-access cocaine self-administration paradigm. Once 
rats acquired, maintained, and extinguished their cocaine intake and seeking, 
they were subjected to a mock test. During the mock test, the rat was restrained 
to acclimate them to the microinjection procedure they would encounter during 
the reinstatement test. This was done to control for the stress of being restrained 
and microinjected. On the reinstatement test day, rats were given a bilateral 
infusion of vehicle (saline) or PACAP (100 pmol) into the NAcc paired with an 
injection of cocaine (I.P.,10 mg/kg). A two-way repeated measure ANOVA was 
used to determine differences in drug seeking (lever presses) during the cocaine-
primed reinstatement test relative to a mock test (Figure 4-2 n=10/treatment). We 
report a main effect of PACAP treatment (F1,18=13.03, p<0.05) and test 
procedure (F1,18=45.89, p<0.05) with a significant interaction between these 
variables (F1,18=13.82, p<0.05). Post-hoc tests revealed that 100 pmol PACAP 
treatment significantly reduced drug seeking on the reinstatement test day 
relative to 0 pmol (Tukey, p<0.05). These data demonstrate that PACAP 






While PACAP attenuates drug seeking when exogenously applied to the 
NAcc, the endogenous expression of PACAP, its source, and receptor 
expression profile among astrocytes and neurons in the NAcc is unknown. To 
test if PACAP is endogenous to the NAcc, we sampled extracellular fluid using 
microdialysis and found PACAP to be present (Figure 4-3A). In order to ascertain 
the endogenous source of PACAP in the NAcc, the mPFC to NAcc pathway was 
labeled with a rhodamine retrograde tracer. This pathway in particular was 
chosen due to the relevance of the PFC in executive function and drug seeking 
(B. T. Chen et al., 2013).  Fluorescent cells within the mPFC were extracted 
using fluorescent-activated cell sorting (FACS) and PACAP mRNA was detected 
in rhodamine positive but not rhodamine negative cells (Figure 4-3B). These 
findings demonstrate that PACAP is an endogenous peptide in the NAcc that is 
sourced by afferents from the mPFC. 
 
Figure 4-2: PACAP 
attenuates cocaine-
primed reinstatement 
when infused into the 
NAcc. Data depicts 
number of lever presses 
during the reinstatement 
test relative to a mock 
injection test. Subjects 
were infused with PACAP 
or Saline bilaterally in the 
NAcc in conjunction with a 
10 mg/kg cocaine 
injection I.P. *effect of 
PACAP treatment relative 
to vehicle p<0.05; # effect 
of PACAP treatment 





Given the expression of PACAP in the NAcc we next investigated what the 
molecular effects of PACAP signaling in the NAcc are. Currently, the PACAP 
receptor expression profile and their functional impact in astrocytes and neurons 
within the NAcc are unknown. First, we isolated NAcc astrocytes from the GFAP: 
GFP-Lck transgenic rat via FACS so their PACAP receptor expression profile 
could be determined (Figure 4-4A). PCR products for xCT, PAC1R and VPAC2 
were detected with GFAP and GAPDH as positive controls and NeuN as a 
negative control.  Importantly, PACAP mRNA was not present in NAcc astrocytes 
which suggests they are not a source of PACAP.  
Next, the effect of PACAP signaling on glutamate transporters in 
astrocytes was investigated. In the previous chapter we learned that PACAP 
(100 nM) increases Sxc-dependent cystine-evoked glutamate release from  
Figure 4-3. PACAP is 
present in the NAcc and is 
expressed in the mPFC to 
NAcc pathway. A, Diagram 
depicting microdialysis probe 
placement in the NAcc with 
PACAP concentration (pM). 
B, PCR products from FACS 
isolated rhodamine positive 
mPFC to NAcc neurons and 
rhodamine negative cell 
populations. D1R/D2R, 





striatal astrocytes. Here, we chose to investigate whether PACAP is influencing 
astrocytic EAAT function by measuring D-aspartate uptake (Figure 4-4B). The 
Michaelis-Menten equation was used to estimate changes in transport kinetics. 
This model equation strongly fit clearance in both vehicle and PACAP treatment 
groups (n=3-4/treatment, p<0.05) and explained 93% and 91% of the variability 
in the data, respectively. Relative to vehicle, PACAP produced marginal changes 
in D-aspartate transport kinetics (Km, 96.26 to 97.95 µM; Vmax, 58.90 to 63.17 
µg/mg). Collectively, these data suggest that PACAP receptors are expressed by 
Figure 4-4: PACAP signaling in astrocytes does not impact D-aspartate 
uptake.  A, PCR product from FACS isolated NAcc astrocytes. B, In vitro D-
aspartate clearance with and without 100 pmol PACAP applied for 30 minutes. 




astrocytes in the NAcc and PACAP signaling does not appear to rapidly impact 
on broad EAAT function.  
Having established the presence of PACAP receptors in astrocytes and 
the effect they have on Sxc and EAATs, we next investigated the impact of 
PACAP signaling on NAcc efferents. First, we investigated PACAP receptor 
expression in the two major efferents from the NAcc: the direct pathway to the 
substantia nigra and the indirect pathway to the ventral pallidum. Both pathways 
were labeled with rhodamine tracer and single cells were extracted. PCR 
products for the dopamine receptors match established data (Kupchik et al., 
2015) serving as a positive control, and PACAP receptors appear to be 
expressed in both pathways (Figure 4-5A,D). Intriguingly, the GluN2B subunit 
appears to only be expressed in the direct pathway.  
Given the presence of PACAP receptors in both pathways, we next tested 
the physiological impact of PACAP signaling by measuring evoked EPSCs in 
labeled efferent pathways. In the direct pathway, PACAP (100 nM) significantly 
attenuated EPSC amplitude relative to baseline (Figure 4-5B; n=8; t13=2.91, 
p<0.05) whereas in the indirect pathway, PACAP (100 nM) produced an increase 
relative to baseline (Figure 4-5E; n=8; t21=2.59, p<0.05). Next, we investigated 
the contribution of NMDAR current to the pathway specific effects of PACAP 
signaling considering the expression of GluN2B is specific to the direct pathway. 
Intriguingly, PACAP enhanced NMDAR mediated current even at hyperpolarized 
holding potentials where Mg2+ block would otherwise prevent current 





indirect pathway (Figure 4-5F, n=7-8/treatment, p>0.05). These data 
demonstrate that PACAP attenuates EPSCs but enhances NMDAR current 
independent of holding potential in the direct pathway, but enhances EPSCs in 
the indirect pathway while not impacting NMDAR currents.  
Given that the effect of PACAP on EPSCs and NMDAR current is specific 
to the direct pathway, we next chose to investigate if PACAP is interacting with 
D1R or GluN2B containing NMDAR signaling since the expression profile of 
these two receptors appears to be the only difference among the two pathways. 
First, we determined if PACAP and D1R signaling are interacting to influence  
Figure 4-5: PACAP signaling in NAcc efferents differentially tunes excitatory output. 
A,D, PCR  product from fluorescently labeled single cells from the direct and indirect pathway 
respectively. B,E, Data depicts evoked EPSCs from direct and indirect pathway MSNs, 
respectively, with and without PACAP treatment. C,F, IV curves depicting the effect of 
PACAP on NMDA mediated currents on direct and indirect pathway MSNs respectively. T-
test, *p < 0.05; **p <0.01. Special thanks to Dr. Matt Hearing for collecting cells for A,D and 






reinstatement of drug seeking. Following a long-access cocaine self-
administration paradigm, WT rats were subjected to a microinjection of the D1R  
agonist SKF (2 µg/side), PACAP (100 pmol), or a combination of both into the 
NAcc (Figure 4-6). No cocaine was given during this reinstatement test. A one- 
way ANOVA revealed a significant effect of treatment (F3,36=12.437; p<0.05). A 
Tukey test revealed a significant increase in drug seeking following SKF 
treatment relative to the vehicle (DMSO) control (p<0.05). When PACAP was co-
administered with SKF, drug seeking was significantly attenuated relative to SKF 
alone (Tukey, p<0.05), but remained heightened relative to controls (Tukey, 
p>0.05). These data suggest that D1R agonism is sufficient to increase drug 
seeking which is partially blocked with the co-administration of PACAP which 
suggests that dopamine and PACAP signaling are interacting to influence the 
reinstatement of drug seeking. 
 
Figure 4-6: PACAP 
attenuates D1 receptor 
agonist-primed 
reinstatement. WT rats 
were infused with 
combinations of PACAP 
and SKF, a D1 receptor 
agonist during a 
reinstatement test. 
Cocaine was not 
administered. *effect of 
treatment relative to 
control p<0.05; #effect of 






The enhancement of NMDAR current while attenuating evoked EPSCs in 
the direct pathway is suggestive of a net inhibitory effect of NMDARs on EPSCs. 
Considering the pathway specificity of GluN2B we applied the GluN2B antagonist  
RO 25-6981 (RO) to direct pathway neurons in conjunction with PACAP, which 
revealed that GluN2B antagonism prevented PACAP from attenuating EPSCs 
(Figure 4-7A; n=7; t11=2.97, p<0.05). Furthermore, the contribution of Sxc to this  
effect was also tested on slices from MSxc rats which revealed that PACAP 
could not attenuate EPSCs in the absence of Sxc (Figure 4-7B; n=7; t12=3.09, 
p<0.01). These data reveal that PACAP attenuates evoked EPSCs and 
enhances NMDAR mediated current in the direct but not indirect pathway and 
these effects require GluN2B and Sxc.  
Figure 4-7: PACAP signaling requires Sxc and GluN2B to attenuate direct pathway 
evoked EPSCs.  A, Data depicts evoked EPSC amplitude from direct pathway MSNs co-
treated with PACAP ± RO-25-6981, a use-dependent GluN2B antagonist. B, Evoked EPSC 
amplitude from WT and MSxc rat direct pathway MSNs treated with and without PACAP 






Given the attenuation of EPSCs in the direct pathway, we hypothesized 
that this may be due to a change in AMPAR and NMDAR phosphorylation in the 
NAcc. Two sites were investigated: T840 of GluA1 and S897 of GluN1. Given our  
previous data showing a link between T840 and Sxc as well as the 
aforementioned reduction by PACAP in hippocampal neurons (Toda & Huganir, 
2015), we hypothesized that PACAP would decrease T840 in the NAcc. Indeed, 
a t-test revealed a significant reduction in the ratio of GluA1 phosphorylation at 
residue T840 to total GluA1 in rats microinjected with PACAP (100 pmol) into the 
NAcc relative to vehicle controls (Figure 4-8A; pT840/GluA1, n=7-8/treatment, t13 
= 2.178; p<0.05).  
Regarding S897 of GluN1, which is important for trafficking NMDARs to 
the synapse (B. Li et al., 2009), we hypothesized that PACAP signaling may be 
moving NMDARs away from the synapse, putting them in a position to receive 
Sxc-derived glutamate. A t-test revealed a significant reduction in the ratio of 
GluN1 phosphorylation at residue S897 to total GluN1 as a result of PACAP 




GluA1 and GluN1 in the 
NAcc. A,B, 
Representative western 
blots from NAcc tissue 
samples from WT rats 
injected with V, vehicle 
or P, PACAP 100 pmol. 










These data suggest that PACAP influences GluA1 and GluN1 function in the 
NAcc by changing the phosphorylation of key residues that dictate the 
localization and or function of AMPARs and NMDARs. These biophysical  
changes correlate well with the finding that PACAP produces a net inhibition of 
EPSCs through a Sxc and GluN2B dependent mechanism.  
Having demonstrated the necessity of GluN2B and Sxc for PACAP’s 
ability to attenuate EPSCs in the direct pathway, we next tested their necessity in 
regulating drug seeking behavior. WT and MSxc rats were subjected to a long-
access cocaine self-administration paradigm. During the reinstatement test, rats 
were given a cocaine injection in conjunction with infusion of vehicle control, 
PACAP, RO, or both into the NAcc (Figure 4-8). A two-way ANOVA revealed a 
main effect of treatment (F3,52=5.646; p<0.05), no effect of genotype (F1,52=3.666; 
Figure 4-9: PACAP signaling requires Sxc and GluN2B to attenuate cocaine-
primed reinstatement. WT and MSxc rats were infused with one of four 
treatments in conjunction with a 10 mg/kg cocaine injection I.P. *effect relative to 
vehicle p<0.05. #effect of treatment within genotype p<0.05. 
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p>0.05), but a significant interaction between these variables (F3,52=10.148; 
p<0.05). Post-hoc tests revealed PACAP attenuated reinstatement in WT (Tukey, 
p<0.05) but not MSxc rats (Tukey, p>0.05) relative to vehicle. RO did not 
significantly impact cocaine seeking in WT rats (Tukey, p>0.05), but did prevent 
the attenuation of seeking when co-administered with PACAP (Tukey, p<0.05, 
relative to PACAP alone; p>0.05, relative to vehicle). In MSxc rats, RO 
attenuated drug seeking (Tukey, p<0.05, relative to vehicle) even in the presence 
of PACAP (Tukey, p<0.05, relative to PACAP alone). These data suggest that 
the effects of PACAP on cocaine seeking require Sxc and GluN2B, but there are 
genotypic differences in the effect of RO. 
DISCUSSION 
The purpose of these experiments was to investigate how neuronal and astrocyte 
signals are coordinated in the NAcc to alter network output and impact cognitive 
control in drug seeking. These data demonstrate that the neuropeptide PACAP, 
which is expressed by the mPFC to NAcc afferent, is able to attenuate drug 
seeking via a multi-cell signaling mechanism that coordinates glutamate release 
from astrocytes via Sxc and ligand binding of this signal in neurons by GluN2B 
containing NMDARs. Remarkably, PACAP can precisely enhance NMDAR 
current in the direct but not indirect pathway which results in a net inhibition of 
evoked EPSCs. This phenomenon mimics a long-term depression-like 
mechanism with the key features of astrocytic glutamate recruitment and 
biophysical adaptation of neuronal NMDARs which collectively dephosphorylate 





direct pathway corresponds to reduced cocaine-primed reinstatement of drug 
seeking. 
 
The effect of acute PACAP application to astrocytes demonstrates rapid 
increases in Sxc-mediated cystine-evoked glutamate release with no changes to 
broad EAAT function as measured by D-aspartate uptake. Previous studies had 
shown that the expression and function of Sxc, measured by cystine uptake, is 
increased following 24-hour or greater application of PACAP (Kong et al., 2016; 
Resch et al., 2014). Similarly, GLT-1 expression and function were upregulated 
by PACAP following a 72-hour incubation (Figiel & Engele, 2000). Given the 
Figure 4-10: Multi-cell 
signaling mechanism 
for PACAP signaling in 
the NAcc. PACAP 
sourced from the mPFC 
signals through 
astrocytes to enhance 
Sxc function while also 
signaling through 
neurons to localize 
NMDA receptors to the 
extrasynaptic 
compartment to receive 
astrocytic glutamate. 
This produces an 
inhibitory effect on 
GluA1 function in the 





timescale of these changes, it is unlikely that these effects would be responsible 
for the rapid behavioral effects of PACAP. Thus, more rapid assays consisting of 
30-minute PACAP treatment were conducted. While not much is known about 
post-translational modifications to xCT that produce changes in Sxc-dependent 
glutamate release, PACAP signaling may produce a change in phosphorylation 
status at one or more of the three putative regulatory sites S26, S185, or S481 to 
enhance transport efficiency. Furthermore, the lack of changes in EAAT function 
at 30 minutes suggests this specific effect may be restricted to long-term effects 
of PACAP signaling. Collectively, the principle effect of PACAP signaling in 
astrocytes is enhancement of glutamate release via Sxc. 
The impact of PACAP signaling on the direct pathway is significant given 
the established roles of striatal efferents in reward seeking. When D1R positive 
neurons are stimulated optogenetically, cocaine-conditioned place preference 
and cocaine induced locomotor activity is enhanced, with the opposite effect 
occurring when D2R positive neurons are stimulated (Lobo et al., 2010).  A major 
unanswered question is how PACAP can selectively regulate the direct pathway, 
given its receptors appear in both efferents. Preliminary evidence suggests that 
the GluN2B subunit is specifically expressed by the direct pathway, which may 
explain why this pathway is regulated by Sxc. Another major difference between 
the two pathways according to our data is the expression of the dopamine 
receptors D1R and D2R with the direct pathway exclusively expressing D1R and 
the indirect pathway expressing a mix of D1R and D2R. Importantly, D1Rs have 
been shown to enhance AMPAR mediated signaling through increased trafficking 
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to the membrane (Chao, Ariano, Peterson, & Wolf, 2002; Gao, Sun, & Wolf, 
2006). Since PACAP has a net inhibitory effect on AMPAR signaling, we were 
curious about the potential interaction between PACAP and dopamine signaling 
on cocaine seeking. Our data revealed that PACAP and D1R signaling interact to 
regulate drug seeking with PACAP attenuating but not blocking D1R agonist 
induced reinstatement.  
Mechanistically, it is likely that PACAP and dopamine are interacting at the 
AMPAR to gate excitatory output in the direct pathway. In support, application of 
SKF to NAcc neurons increases GluA1 insertion into the membrane (Chao et al., 
2002). A follow up study, albeit in hippocampal neurons, demonstrated that 
GluA1 was preferentially inserted into the extrasynaptic compartment and 
subsequently laterally diffused into the synapse following NMDAR stimulation via 
glycine (Gao et al., 2006). Within the context of our findings, this mechanism is 
significant because the initial insertion of GluA1 into the extrasynaptic 
compartment puts them in optimal position to be regulated by extrasynaptic 
NMDAR. If the two-cell PACAP signaling mechanism is engaged, the newly 
inserted D1R-dependent GluA1 would be dephosphorylated at T840 and thus 
functionally dampened prior to their lateral diffusion into the synapse. In this way, 
PACAP receptors and D1Rs are competing for control over AMPAR function and 
ultimately control over direct pathway MSNs and reward seeking behavior. 
Certainly, more research is required to understand the electrophysiological and 
molecular factors that may be influencing this mechanism. 
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The expression of PACAP in the PFC afferent to the NAcc is significant 
finding for the addiction field and may explain why Sxc function in the NAcc is 
reduced following drug intake. Disruption of the mPFC to NAcc pathway has 
been suggested to be critical for the reinstatement of cocaine seeking. In 
particular, long-term cocaine self-administration can broadly reduce the 
excitability of PFC pyramidal neurons and when these neurons are 
optogenetically stimulated, cocaine seeking is reduced (B. T. Chen et al., 2013). 
One interpretation in line with our results is that neurons containing PACAP 
projecting to the NAcc are being activated which is producing the reduction in 
seeking. It could be that over the course of drug intake, the PFC is taken off-line 
and PACAP is no longer being released into the NAcc from this afferent, which 
causes Sxc function to decrease. By infusing PACAP into the NAcc during a 
reinstatement test, we are rectifying this reduction. However, this does not rule 
out the possibility that other glutamatergic NAcc afferents such as from the 
basolateral amygdala which are also critical for cocaine seeking (B. R. Lee et al., 
2013) may contain PACAP. Future research should be aimed at determining 
whether dysregulation in PACAP production or release from NAcc afferents is 
predictive of the propensity for relapse. 
While speculative, PACAP may encode qualitative information about 
incoming stimuli; signaling to local astrocytes that the incoming stimulus 
information is strong and requires astrocytes to help in processing and 
disseminating this information to the network. Importantly, peptides are typically 
released from neurons under different circumstances relative to small 
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neurotransmitters, including specific patterns of firing or long durations of activity 
(Cropper, Jing, Vilim, & Weiss, 2018). Thus, the information coming from the 
mPFC or possibly other NAcc afferents is likely specific to the environmental 
circumstances and PACAP is released to signal to astrocytes that they are 
needed to process this information. Given the actions of PACAP, it may encode 
negative feedback about the probability of a rewarding outcome, which may be 
why it potently blocks reinstatement.  
The biophysical adaptations of GluA1 and GluN1 produced by PACAP are 
consistent with and expand on previously established findings. PACAP signaling 
in hippocampal neurons results in a reduction in pT840/GluA1. Importantly, this 
phenomenon requires NMDAR activation (Toda & Huganir, 2015). We found that 
PACAP in the NAcc can produce the same reduction in pT840 which coincided 
with enhancement of NMDAR currents and an attenuation of evoked EPSCs in 
the direct but not indirect pathway. Intriguingly, PACAP was able to enhance 
NMDAR currents even at holding potentials where Mg2+ block would otherwise 
be present. One interpretation of this is that PACAP is altering NMDAR to make 
them resistant to Mg2+ allowing them to be more rapid in their signal transduction 
capabilities rather than coincidence detectors that require sufficient antecedent 
AMPAR mediated depolarization. In support of this theory, protein kinase C 
(PKC) reduces Mg2+ block of NMDARs (L. Chen & Huang, 1992) and PACAP 
activates PKC (Macdonald et al., 2005). The reduction in Mg2+ block allows any 
neuron in the network that contains these modified NMDARs to be disengaged in 
a synchronized fashion independent of activity state, which could be argued as 
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an incredibly powerful and efficient inhibitory signal. Despite this, a lingering 
question remains; how is PACAP able to do this in a pathway specific fashion 
even though its receptors appear to be expressed by both efferents?  
One interpretation of the pathway specific effects of PACAP is that only 
the astrocytes that are interacting with the direct pathway contain Sxc and 
therefore PACAP and Sxc can only effectively alter that network. On the other 
hand, the NMDAR encoding Sxc-derived glutamate may only be expressed by 
the direct pathway. Preliminary evidence suggests that only the direct pathway 
contains the GluN2B subunit. This is a controversial claim, which will require 
more research to fully investigate, but the findings that GluN2B is necessary for 
the effects of PACAP on EPSC amplitude in the direct pathway and consequently 
drug seeking behavior support this interpretation. Furthermore, there was 
evidence that PACAP enhances EPSCs in the indirect pathway. It is not clear 
whether Sxc is involved in this regulation. The enhancement of the indirect 
pathway could be due to PACAP signaling through its receptors on these 
neurons to increase phosphorylation of residue S845 of GluA1 which has been 
shown to enhance the synaptic retention and ion conductance of AMPARs 
(Diering, Heo, Hussain, Liu, & Huganir, 2016; Toda & Huganir, 2015). If GluN2B 
is not expressed by the indirect pathway, T840 of GluA1 is unlikely to be 
impacted which places AMPARs in an enhanced rather than inhibited state 
following PACAP treatment.  
The finding that pS897/GluN1 is dephosphorylated because of PACAP 
signaling is novel and suggests that neural signals can control glutamate 
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receptor localization. When pS897/GluN1 is mutated into a phospho-resistant 
residue, the expression of GluN1 and GluA1 significantly decreases in 
hippocampal synapses which coincides with an impairment in LTP induction (B. 
Li et al., 2009). Since PACAP is dephosphorylating pS897/GluN1, it should 
reduce synaptic localization of GluN1. It is unclear if these receptors are 
internalized or lateralized into the extrasynaptic compartment, but in either 
scenario, extrasynaptic NMDAR would likely be dominant. Given that 
pT840/GluA1 is a pro-synaptic enrichment marker regulated by NMDAR 
activation, the net outcome of this extrasynaptic NMDAR signal is likely 
dephosphorylation of pT840/GluA1 which produces an LTD-like effect. Given 
PACAP’s actions on NMDAR mediated and evoked EPSCs, it is likely 
destabilizing synaptic glutamate receptors in a pathway specific manner thus 
reducing their ability to encode synaptic glutamate. 
The ability of astrocytes to potentiate and depress neural networks is 
emerging as a fundamental principle of brain function (Martin et al., 2015). Initial 
investigations into this phenomenon revealed the role of D-serine release from 
astrocytes, an NMDAR co-agonist, in the potentiation of synapses in the 
hippocampus (Henneberger, Papouin, Oliet, & Rusakov, 2010). This release 
mechanism has been demonstrated to be sensitive to intracellular Ca2+ and 
dependent on vesicular fusion. However, the causative factors or receptors that 
drive this mechanism remain unclear, but theoretically any factor that can 
produce broad changes in Ca2+ within an astrocyte could be involved. PACAP 
signaling through its Gq coupled receptors could theoretically trigger Ca2+ 
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transients in astrocytes, but other factors we previously explored such as 
endocannabinoids could also engage this mechanism. Future experiments 
should be aimed at discerning the intracellular signaling cascades triggered by 
PACAP signaling and whether they are sufficient to induce release of non-
glutamatergic gliotransmitters that modify neural networks. 
The reinstatement data from WT and MSxc rats reveals how GluN2B can 
have different effects on cocaine seeking depending on Sxc activity. In WT rats 
treated with cocaine and RO, which represents basal Sxc activity, there was no 
significant effect on cocaine seeking relative to vehicle. With a PACAP treatment, 
which represents enhanced Sxc function, cocaine seeking is reduced, but if RO 
is co-administered, this reduction is blocked. Conversely, in MSxc rats, which 
represents an absence of Sxc activity, cocaine with RO alone is sufficient to 
attenuate cocaine seeking and PACAP is unable to alter cocaine seeking with 
RO present. This suggests the following: when Sxc activity is unaltered, GluN2B 
has minimal impact on cocaine seeking. When Sxc activity is enhanced, GluN2B 
is involved in attenuating cocaine seeking and when Sxc activity is absent, 
GluN2B drives drug seeking. From a therapeutic perspective, this highlights the 
difficulty in targeting receptors to treat disorders; the efficacy and behavioral 
outcome of the drug may be different depending on, in this instance, the status of 
glutamate release from astrocytes. Given the multitude of biological variables 
that could impact drug efficacy such as time of day, bioavailability, and sex, it is 




Collectively, these data demonstrate that PACAP signals through 
astrocytes and neurons to coordinate astrocytic release and neuronal reception 
of glutamate. This dual-cell signaling mechanism attenuates excitatory output in 
the direct but not indirect pathway and attenuates cocaine-primed reinstatement 
of drug seeking which requires Sxc and GluN2B. It is possible that PACAP is 
encoding stimulus information from the mPFC that signals to astrocytes that they 
are needed to help process this information and actualize it into a functional 
output through regulating specific NAcc efferents. From a therapeutic 
perspective, PACAP has revealed the significance of Sxc and GluN2B in 
regulating drug seeking behavior. Given the emerging literature on Sxc-targeting 
compounds and the recent approval of NMDAR targeting drugs such as 
Esketamine for severe depression by the FDA (Gould, Zarate, & Thompson, 
2019), it is possible that we have begun to unveil novel therapeutic targets as a 
result of an increased understanding of intercellular communication involving 
astrocytes. However, our behavioral data reveals that more research will need to 
be done to understand how manipulating GluN2B signaling can have varying 
outcomes on cocaine seeking. Ultimately, these findings might have therapeutic 









PERSPECTIVES ON THE IMPORTANCE OF SYSTEM XC-  




The goal of these studies was to investigate the novel idea that the 
evolutionary expansion of signaling complexity between brain cells contributed to 
evolutionary gains in cognitive ability. Progress in this area has the potential to 
transform efforts to treat cognitive dysfunction that is present in an array of CNS 
disorders. The primary benefit of the findings reported here was to illustrate the 
relevance of signaling mechanisms in astrocytes, which are among the most 
abundant cells in the human brain. Specifically, we provide novel support for the 
hypothesis that evolutionarily-new glutamate signaling mechanisms expressed 
by astrocytes are selectively required for complex forms of cognition.  
Our study of astrocyte signaling focused on the characterization of the 
cysteine-glutamate antiporter Sxc. We were interested in studying Sxc function 
from the molecular to the behavioral level.  As discussed below, our data 
provides preliminary insights into how Sxc has been integrated into neuronal and 
tripartite signaling mechanisms (Figure 5-1) to produce complex regulation of 
behavioral control. However, the ultimate significance of these studies will be 












The Significance of Sxc to the Tripartite 
 The significance of glutamate release from astrocytes to signaling within 
the tripartite is evidenced by our findings that Sxc in the NAcc influences 
neuronal (e.g., ionotropic glutamate receptors) and astrocytic (glutamate 
transporters) signaling mechanisms, and that it in turn is regulated by multiple 
neuronal mechanisms (e.g. PACAP, endocannabinoids). In support, a loss of Sxc 
impaired astrocytic EAAT function, which would likely produce an increase in 
synaptic (and extrasynaptic) concentrations of extracellular glutamate. 
Additionally, a loss of Sxc does not appear to impact presynaptic release of 
glutamate, which was surprising given a previously established link between the 
two (Baker et al., 2002). However, Sxc activity was found to contribute to the 
tuning of glutamate signaling within the synapse by negatively regulating AMPAR 
function, an effect that we and others indicate is likely mediated by extrasynaptic 
NMDARs (Delgado et al., 2007). Regulation of AMPAR function likely involves 
the regulation the phosphorylation of GluA1, specifically residue GluA1 T840, 
Figure 5-1: How PACAP and Sxc fit into the model of tripartite synapse function. The 
major advancements of this work are highlighted by the inclusion of PACAP, its receptors, 
and the net outcome of the intercellular communication produced by its signaling. PACAP is 
released by afferents from the mPFC, and possibly other afferents and is received by 
receptors expressed by neurons and astrocytes. Within astrocytes, PACAP enhances Sxc-
mediated glutamate release. In neurons, PACAP likely facilitates dephosphorylation of 
GluN1 at S897 which concentrates NMDARs in the extrasynaptic compartment. Here, 
GluN2B containing NMDARs encode glutamate released by Sxc and display enhanced 
conductance even during hyperpolarized potentials. The significance of this phenomenon is 
that antecedent depolarization via AMPARs is not required to remove Mg2+ block from the 
NMDAR which allows Sxc to activate the NMDAR of silent neurons. Activation of GluN2B 
inhibits evoked EPSCs, likely through the dephosphorylation of GluA1 at T840. This cellular 
and molecular mechanism specifically attenuates the direct pathway from the NAcc to the 
substantia nigra pars compacta (SNpc) which effectively gates the ability for this pathway to 
elicit a behavioral response.  
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that has been shown to influence AMPAR clustering in the synapse (Williams & 
Featherstone, 2014). This is an important finding because the regulation of 
synaptic transmission by numerous signaling mechanisms, including dopamine 
transmission (Chao et al., 2002; Gao et al., 2006), may involve the regulation of 
AMPARs.  Hence, these receptors appear to be a site of convergence for highly 
disparate signaling mechanisms within the tripartite.   
Much of what we learned about the molecular and cellular roles for Sxc 
involved its actions in the NAcc. We found that Sxc contributes to the gating of 
NAcc efferent pathways in a manner that regulates behavior. In particular, a 
surprising finding was the apparent involvement of Sxc in suppressing the activity 
of the direct pathway (NAcc-SN) although there was not a clear effect of loss of 
Sxc on the second major efferent, the indirect pathway (NACC-VP). Given that 
the direct pathway is canonically viewed to drive motivated behavior (Bromberg-
Martin et al., 2010; Lobo et al., 2010), the regulation of this pathway by Sxc 
suggests that astrocytes contribute to local processing of incoming information to 
modify behavioral output. Presumably, Sxc activity in other structures, such as 
the prefrontal cortex, also functions to provide complex, potentially pathway-
specific gating of afferent and/or efferent outputs in a manner that facilitates 
cognition.  
A critical issue we examined was how Sxc-dependent astrocyte to neuron 
signaling is regulated. While astrocytes are increasingly implicated in the 
regulation of neural circuits, there is a need to understand how glutamate release 
from astrocytes is coordinated with neuron to neuron signals. First, we examined 
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the regulation of Sxc by mechanisms often linked to the control of neuron-neuron 
signaling by determining the capacity of corticosterone, endocannabinoids, and 
PACAP to produce rapid changes in Sxc activity. In part, these mechanisms 
were selected because they reflect control provided by presynaptic neurons, 
postsynaptic neurons, and circulating hormones. We found each of these 
signaling mechanisms to exert rapid regulation of Sxc activity. The ability for 
these factors to influence Sxc suggests that even though Sxc is astrocytic and 
evolutionarily-new, it has become integrated into the tripartite.  
An exciting question that remains to be answered is at what point on the 
evolutionary timescale did neural and hormonal factors develop the ability to 
influence Sxc function. To address this question, we searched for putative 
consensus phosphorylation sequences on xCT, and then mapped their 
appearance on the evolution of vertebrates to find three conserved regulatory 
sites, S26, S185, and S481. S481 is interesting considering this site exists in 
mammals but no other vertebrates. In contrast, S26 is only expressed in some 
birds and mammals. Because these serine residues are targeted by MSK1, 
which is downstream of glucocorticoid, PACAP, and MAP kinase signaling (Beck 
et al., 2013; Butcher et al., 2005), an important question that remains is how 
PACAP and corticosterone signaling interact to influence the phosphorylation of 
these residues and consequently change Sxc function. Furthermore, why certain 
organisms have these regulatory sites versus others needs to be answered as it 
will help illuminate their biological significance. Given these findings, Sxc has 
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been evolving in vertebrates to engrain itself into the processing of information 
provided by neurons and the hormonal milieu. 
The Role of PACAP in Shaping Sxc-Mediated Astrocyte to Neuron Signaling 
The regulation of Sxc by PACAP was especially intriguing to us largely 
due to the profound effects that this neuropeptide has been shown to produce on 
glutamate transporters and receptors (Figiel & Engele, 2000; Kong et al., 2016; 
Resch et al., 2014; Toda & Huganir, 2015). As a result, we chose to investigate 
this Sxc-regulatory mechanism in greater detail. We found PACAP to be 
expressed by mPFC-NAcc neurons and is present in the interstitial space of the 
NAcc. Collectively, these are the first data to implicate PACAP as a neuropeptide 
in NAc afferents. The distribution of PACAP receptors provided interesting 
insights into its function.  We found that PACAP appears to enable, and possibly 
control the impact, of Sxc-mediated astrocyte to neuron signaling by acting on 
both astrocytes and potentially receptive neurons. 
PACAP receptors were detected in NAcc astrocytes, which likely explains 
how this neuropeptide is able to exert rapid regulation of cystine-evoked 
glutamate release by Sxc. To our surprise, the capacity of PACAP to regulate 
astrocytic glutamate mechanisms did not extend to rapid control of EAAT 
function as measured by D-aspartate uptake. However, this does not rule out the 
possibility that PACAP may engage glutamate transporters other than Sxc and 
EAATs to regulate extracellular glutamate. 
Neuronal PACAP receptors may define the nature or impact of incoming 
signals from astrocytes. First, we learned that PACAP dephosphorylates GluN1 
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at residue S897. This is interesting because this site has been shown to promote 
diffusion of the NMDA receptor out of the synapse (B. Li et al., 2009), where it 
may be exposed to Sxc-released glutamate.  Second, neuronal PACAP signaling 
appears to relieve NMDAR blockade by Mg2+.  This unexpected finding may add 
to a limited body of work indicating that Mg2+ blockade is a powerful form of 
NMDAR regulation by intracellular signaling pathways (L. Chen & Huang, 1992; 
Hahn, Wang, & Margeta, 2015; Moriguchi et al., 2007; Tyszkiewicz, Gu, Wang, 
Cai, & Yan, 2004).   In the absence of PACAP-induced removal of Mg2+ 
blockade, Sxc-activation is unlikely to stimulate extrasynaptic NMDA receptors.  
Instead, Sxc regulation of neuronal function is traditionally linked to metabotropic 
receptors (M. M. Moran et al., 2005; Moussawi et al., 2011). Hence, the question 
becomes, how might activation of extrasynaptic NMDARs produce unique 
changes to neuronal activity? Extrasynaptic NMDARs have been shown to inhibit 
synaptic transmission by altering the phosphorylation of multiple residues of the 
AMPAR subunit GluA1, (Delgado et al., 2007; Toda & Huganir, 2015). Consistent 
with this, we observed PACAP-induced suppression of synaptic transmission, 
which was dependent on both Sxc and GluN2B-expressing NMDARs.   
The attenuation of synaptic activity by PACAP-mediated Sxc to NMDA 
signaling was pathway specific, which raises the possibility that PACAP also 
determines which cells are impacted by Sxc-mediated astrocyte to neuron 
signaling. In support, we observed PACAP-induced regulation of NMDA receptor 
function and synaptic activity in the direct but not the indirect pathway.  Similarly, 
we observed pathway-specific differences in expression of the various PACAP 
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receptors and in the expression of GluN2B.  While these preliminary 
observations require further study, these findings provide a potential mechanism 
illustrating how astrocytes can produce cell- and pathway-specific regulation of 
synaptic activity even when maintaining tonic glutamate concentrations 
throughout the diffuse, interstitial space.   
In addition to discrete signaling mechanisms such as PACAP, the complexity of 
the tripartite may contain forces regulating glutamate receptor activation. For 
example, we have long assumed that extrasynaptic, interstitial concentrations of 
glutamate were relatively homogenous, and therefore displayed a volume 
transmitter type of signaling. This information has been used to form predictions 
about extracellular glutamate concentrations, receptor affinity for glutamate, and 
patterns of receptor activation. To the extent that we considered areas of 
extracellular glutamate to display spatial-dependent differences in concentration, 
the assumption was that equilibrium in glutamate concentration was solely due to 
a diffusion pattern determined by concentration gradients.  However, modern 
findings in neuroscience indicate that it may time to reexamine what we think we 
know.  
Is Sxc-NMDAR Signaling Impacted by the Structure of the Extrasynaptic Space? 
Is glutamate movement in the interstitial space solely determined by 
glutamate concentration? This is often assumed to be the case in the 
extrasynaptic space.  Specifically, we have long assumed that astrocytes 
maintain a near homogenous concentration of glutamate that reflects the relative 
affinity of glutamate receptors.  Theoretically, a much more efficient and effective 
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mode of intercellular signaling would be a system in which the release site of 
glutamate was targeted toward the receptive site (e.g., the receptor populations) 
akin to the synapse.  In the context of our findings, the question is whether 
PACAP enables a very specific signaling axis between astrocytes and neurons 
by the precise targeting of NMDARs. A critical advantage of this system would be 
the capacity to create multiple, functionally distinct, signaling microdomains that 
could be more efficiently maintained due to the reduced need of extracellular 
glutamate molecules.  The reduction in the number of glutamate molecules would 
be due to the reduction in the extracellular space requiring a set concentration of 
glutamate that would be capable of activating the receptor. 
The extracellular matrix, which represents the structural foundation of 
neural circuits, is gaining recognition for its role in compartmentalizing the brain 
to create the types of signaling efficiencies described above (Dityatev et al., 
2010). An important question is whether the extracellular matrix physically links 
astrocytic Sxc with neuronal glutamate receptors that are trafficked into the 
appropriate zone in a cell- and signal- specific manner. Again, this would mimic  
vesicular release machinery, which adheres to adjacent post-synaptic density 
proteins (Christopherson et al., 2005; Eroglu et al., 2009; Hata et al., 1993; Kania 
& Klein, 2016; Kucukdereli et al., 2011).  
Assessing the likelihood that Sxc interacts with the extracellular matrix and 
possibly other transmembrane cellular adhesion proteins on neurons to localize 
to adjacent to NMDARs requires insight into the crystalline structure of the Sxc 
subunits. Importantly, there are two subunits of Sxc, the light chain xCT and 
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heavy chain 4F2hc (or designated as CD98), which is also essential for the 
expression of the light chain in the membrane. CD98 has many light chain 
partners (Mastroberardino et al., 1998) interacting across three domains: 
cytoplasmic, transmembrane, and extracellular all with their unique functions. 
The cytoplasmic and transmembrane domains of CD98 interact with cell 
adhesion proteins such as integrins to facilitate their binding to their extracellular 
ligands (Fenczik et al., 2001). Integrins have a number of different extracellular 
ligands such as components of the basement membrane of the extracellular 
matrix (collagens, tenascins, laminins etc.) and can also facilitate direct cell-cell 
interactions (Humphries, Byron, & Humphries, 2006). The extracellular domain of 
CD98 is important for facilitating amino acid transport through the light chain, i.e. 
xCT, due to the covalent interaction of cysteines within this domain with the light 
chain (Fenczik et al., 2001). Furthermore, CD98 has been well studied by cancer 
researchers due to its ability to interact with cellular adhesion proteins such as 
integrins, which facilitate the migration of cancer cells through the extracellular 
parenchyma (Feral et al., 2005). However, this phenomenon is not limited to 
cancer cells, as a similar phenomenon is observed in epithelial cells (Cai et al., 
2005).  
Likewise, NMDARs also interact with integrins. The interaction between 
integrins and the extracellular matrix or potentially adjacent cellular ligands 
increase the amplitude of NMDAR currents (Lin, Arai, Lynch, & Gall, 2003). 
These findings demonstrate that the function of Sxc and NMDARs are impacted 
by the cellular adhesion protein integrin and that perhaps, Sxc and NMDARs are 
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interacting with the same ligands within the extracellular matrix. A key experiment 
would then be to determine if Sxc and NMDARs co-localize or co-
immunoprecipitate via their association with integrins. If so, it would suggest that 
glutamate signaling within the extrasynaptic compartment follows similar design 
principles to the synaptic cleft by utilizing transcellular protein bridges that 
facilitate high-fidelity intracellular communication between release mechanisms 
and receptors. 
 As introduced above, the extracellular matrix may permit the creation and 
maintenance of discrete signaling zones. Another critical factor in the formation 
of discrete signaling zones is the volume of the interstitial space, which is 
determined by the physical proximity of cellular membranes (often astrocyte and 
neuronal membranes).  Notably, the volume of the interstitial space is regulated 
by neuronal activity, in part by influencing astrocyte swelling. In support, neuronal 
depolarization causes an elevation in extracellular K+ which triggers uptake into 
adjacent astrocytes through inwardly rectifying K+ channels and Na+/K+ 
ATPase. This process produces an osmotic gradient in astrocytes that drives 
water influx through aquaporins causing the astrocytes to swell and thus reduce 
extrasynaptic volume (Hubel & Ullah, 2016). Additionally, glutamate released by 
neurons drive uptake though astrocytic transporters e.g. GLT-1 which co-
transports Na+. This also triggers swelling in the astrocyte and consequently a 
reduction in the extrasynaptic volume (MacAulay, Hamann, & Zeuthen, 2004), 
which can produce an anisotropic diffusion pattern i.e. a biased directionality to 
the flow of glutamate in the extracellular space. Such cellular barriers reduce the 
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mobility of glutamate by producing “dead zones” in the extracellular space that 
impede the flow of signaling molecules and bias glutamate access to specific 
zones within the extracellular domain (Vargová & Syková, 2014). Given these 
findings, synaptic glutamate (or glutamate released into extrasynaptic 
microdomains) could be compartmentalized from synaptic glutamate via cellular 
swelling.   These ideas will require further research, but they provide a clear 
demonstration that a more thorough understanding of the complexity within the 
tripartite may lead to highly novel approaches to understand glutamate signaling 
in health and disease.    
The Significance of Sxc to Cognition 
Our studies provided multiple examples of cognitive dysfunction following 
a loss of Sxc. We found that MSxc rats more readily engage with a reward-paired 
CS (CS+) during the PCA paradigm. Intriguingly, approach toward CS+ was 
maintained even if this behavior was punished by withholding reward delivery. 
This was the first hint that MSxc rats displayed cognitive deficits, which was 
illustrated by an inability to adapt their behavior in response to changing reward 
contingencies and is considered a principle executive function (Diamond, 2013). 
This type of executive dysfunction was also observed during the attentional set 
shifting paradigm, whereby MSxc rats took significantly more trials relative to WT 
rats to adapt a new behavioral strategy to obtain rewards in a maze. Likewise, in 
Kamin fear blocking, attentional gating of extraneous stimuli was disrupted in 
MSxc rats which made them more likely to freeze to stimuli that were otherwise 
weak predictors of danger. These maladaptive associative learning and inflexible 
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perseverative patterns of behavior seen in MSxc rats manifested as an increased 
vulnerability to relapse of cocaine seeking.  
The role of Sxc in cognitive processing appears to depend on the complexity of 
cognition or behavior. As noted above, a loss of Sxc impacted cocaine 
reinstatement, reversal learning, extra-dimensional shift, goal-tracking, and 
Kamin blocking.  In contrast, it did not alter the formation of simple Pavlovian or 
operant associations, novelty-induced locomotion, cocaine self-administration, 
extinction, or fear conditioning. In comparing behaviors impacted versus those 
that are unaltered, it appears that behaviors impacted by a loss of Sxc are 
generally deemed to be more complex and involve top-down processing. These 
data are similar to the pattern of behavior observed by disruption of 
evolutionarily-new components of the synaptic proteome (Nithianantharajah et 
al., 2013). Collectively, these findings lend support to the idea that evolutionarily 
novel biological mechanisms, including those expressed by astrocytes, may 
provide novel opportunities to understand and treat cognitive dysfunction. 
Can a Phylogenetic Strategy Expedite the Development of Effective CNS 
Therapeutics? 
 
 As is the case for most forms of human disease, a key therapeutic 
breakthrough may not be realized until the molecular basis of the pathological 
process is understood to the point of being able to develop effective and safe 
treatments. For CNS disorders, this is exceedingly challenging.   Uncovering the 
basis of cognition is hindered by the exceptional complexity of the brain, which 
makes developing therapies that avoid producing significant side effects 
challenging. For example, the prior sections provide a sense of the complexity 
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that has been revealed within a single tripartite; presumably, this is far from 
complete. Regardless, scaling up the complexity inherent in a single tripartite to 
account for the billions of cells and trillions of signaling microdomains provides a 
useful perspective of the challenge posed by the human brain through 
reductionist approaches.  This has led some investigators to search for a 
different approach to understanding and treating cognitive dysfunction.  
One effective strategy may be to leverage phylogenetics, the study of the 
evolutionary relationships among species at the systemic and molecular level (Z. 
Yang & Rannala, 2012). From this we may be able to discriminate foundational 
neural mechanisms from those that may be selectively involved in enabling 
phylogenetic gains in cognition.  To implement this approach, genes that were 
recently acquired or currently evolving within the vertebrates can be manipulated 
to determine their biological significance (E. J. Vallender, 2008). For example, 
adaptations in the intracellular domain of the GluN2 subunit of NMDA receptors 
expanded the complexity of its downstream signaling partners, which may 
explain the expansion of cognitive ability in vertebrates versus invertebrates (T. 
J. Ryan, Emes, Grant, & Komiyama, 2008).  
Similarly, the four paralogues of Dlg/membrane-associated guanylate 
kinase scaffolding protein in the synapse have evolved in vertebrates to have 
discrete roles in cognitive processing. For example, Dlg1/4 share the greatest 
sequence homology with the ancestral invertebrate Dlg and when knocked out in 
mice can produce unviable mice or significant deficits in basic learning whereas 
Dlg2/3 knockouts have a more unique sequence relative to ancestral Dlg 
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resulting in no deficits in basic learning but only cognitive deficits during complex 
tasks (S. G. Grant, 2016). This suggests that phylogenetics can be used to 
isolate biological components and categorize them based on their involvement in 
fundamental or adaptive brain functions. Identifying these adaptations will be 
critical if we are to understand the molecular origins of what separates our 
cognitive ability from other organisms, and may lead to rapid gains in our ability 
to treat cognitive dysfunction.  
Closing Remarks 
Substance abuse, depression, anxiety, cancer, type 2 diabetes, 
cardiovascular disease, obesity, and schizophrenia represent the most 
debilitating diseases in the modern world. To tackle this disease burden from a 
utilitarian perspective and do the greatest good for the greatest number of people 
possible, we need to approach treating disease by tackling the common 
underlying symptoms. The common symptom in the above disorders is cognitive 
dysfunction (Cannon et al., 2017; Harrison & Wefel, 2018; He et al., 2018; Jones 
et al., 1992; Lange et al., 2017; Millan et al., 2012; P. M. Moran et al., 2008; Rock 
et al., 2014; Y. Yang et al., 2018). Each of these disease states carry an inherent 
inability for the patient to appropriately adapt their behavior in response to their 
internal thoughts and emotions and external environmental circumstances which 
produces an overall reduction in their biological fitness. Solving this problem will 
take a lot of work, and this document represents a paradigm shift in how we can 
investigate novel therapeutic avenues. Using principles from evolutionary biology 
and expanding beyond the neuron and synapse, we can hopefully more easily 
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determine what the molecular basis of cognition in humans is and thus be more 
effective in treating dysfunctional states.  While this work is far from complete, it 
sets the foundation for research into other mechanisms expressed by astrocytes 
that may also contribute to cognitive disorders. While Sxc serves as an intriguing 
therapeutic target a concession can be made that Sxc and more broadly 
astrocytes may not be the solution, but it serves as a well needed paradigm shift 
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